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 Our first study identified the effects of maternal inflammation-induced 
intrauterine growth restriction (MI-IUGR) on growth and muscle glucose metabolism in 
offspring supplemented with curcumin. MI-IUGR lambs exhibited asymmetric growth 
restriction at birth and 30d of age, but normal glucose-stimulated insulin secretion. 
Hindlimb glucose oxidation was reduced by MI-IUGR and not improved by curcumin 
supplementation. Ex vivo muscle glucose oxidation was reduced by MI-IUGR but 
improved somewhat by curcumin. These finding indicate that fetal programming 
responses to MI contribute to neonatal growth and metabolic deficits. Neonatal curcumin 
supplementation had minimal effect on growth deficits but may improve glucose 
metabolism.  
Our second study identified programmed mechanistic changes that explain 
intrinsic functional deficits in myoblasts from maternal hyperthermia-induced IUGR fetal 
sheep. Myoblasts were incubated with TNF⍺,	TNFα with IKK inhibitor (IKKi), or IL6. 
Proliferation in IUGR myoblasts was less than controls in basal and IL6-spiked media. 
IKKi decreased proliferation in all myoblasts, but more in IUGR myoblasts. IUGR 
myoblasts differentiated less than controls, and TNF⍺ further reduced their 
 differentiation. TNFα increased TLR4 mRNA in all myoblasts, but more in IUGR 
myoblasts. TNFR1 and ULK2 mRNA was greater in IUGR myoblasts. IL6 and TNFR1 
mRNA and c-Fos protein were greater in IUGR semitendinosus muscle, but I𝜿B content 
was reduced. These results demonstrate intrinsic enhancement of inflammatory signaling 
and IKK pathways in IUGR myoblasts, which coincided with reduced functional 
capacity.  
A final study assessed stress-responsive mRNA biomarkers in blood. MI at mid-
gestation altered blood mRNA expression in pregnant rats and fetuses. Blood TNFR1 was 
increased in IUGR fetuses, but not when dams received meloxicam. Fetal IL6R and 
maternal TNFR1 were reduced by IUGR with or without meloxicam. We also designed 
ddPCR probes/primers to assess stress-responsive transcripts including 
cytokines/receptors in blood from elephants, cheetahs, and giraffes. These studies 
demonstrate stress-induced changes in blood transcriptomes of animals, which represent 
novel stress biomarkers. 
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Chapter 1: Literature Review 
 
Introduction 
Intrauterine growth restriction (IUGR) is a leading cause of perinatal morbidity 
and mortality in both humans and animals (Alisi et al., 2011). Impaired growth and 
development can result from a plethora of maternal stressors such as obesity, 
inflammation, malnutrition, and environmental stress (Valsamakis et al., 2006). Previous 
studies have linked IUGR to disproportionately reduced skeletal muscle growth during 
prenatal development (Padoan et al., 2004; Yates et al., 2014). IUGR offspring present 
with reduced muscle mass and increased risk of developing metabolic disorders at all 
stages of life (Godfrey and Barker, 2000; Yates et al., 2018). These offspring continue to 
demonstrate deficits in skeletal muscle growth throughout their lifespan (Greenwood et 
al., 2000). Regardless of maternal insult, fetal growth restriction is usually caused by 
reduced nutrient transfer to the fetus due to placental insufficiency leading to IUGR (PI-
IUGR) (Baschat, 2004; Cox and Marton, 2009). This leads to a poor in utero 
environment during development and subjects the fetus to chronic hypoxemia, 
hypoglycemia, hypertension, and hyperlactatemia (Thorn et al., 2011). In response, 
adaptations occur in the fetal tissues to repartition nutrients to vital organs, leading to 
impaired skeletal muscle growth and changes in leukocyte cell populations and 
phenotypes (Godfrey and Barker, 2000; Martinez et al., 2014; Yates et al., 2018). These 
adaptations, although beneficial in utero, lead to impaired metabolic function and 
restricted skeletal muscle growth capacity throughout the lifespan. This “thrifty 
phenotype” was first described by Hales and Barker (1992), who originally linked fetal 
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adaptations that lower birthweight to an increased risk of developing metabolic diseases 
in adulthood. Epidemiological and seminal research studies describe the health outcomes 
of these adaptations (Joyce et al., 2001; Sharma et al., 2016; Camacho et al., 2017b). 
However, little is known about the underlying molecular mechanisms, particularly the 
role that inflammation and other stress system signaling pathways play in the 
development of these adaptions and the resulting IUGR phenotype.  
Fetal Skeletal Muscle Growth and Development 
Forty-percent of total body mass in the uncompromised term fetus is comprised of 
skeletal muscle, which is found predominantly in the hindlimbs, neck and trunk areas 
(Bentzinger et al., 2012; Felber et al., 2013; Brown, 2014). Muscle fibers are composed 
from myoblasts that fuse during early prenatal development to form singular fibers with 
multiple peripherally-located nuclei (Zammit et al., 2006; McCarthy et al., 2011). This 
differentiates skeletal muscle from both cardiac and smooth muscle. Due to the presence 
of actin and myosin filaments, which are responsible for the contraction and function, 
skeletal muscle appears straited. This organ is highly metabolic, relying on both internal 
and external stores of glucose and fatty acids for energy (Bentzinger et al., 2012; Felber 
et al., 2013). Skeletal muscle is active throughout life and after birth continues to undergo 
growth via hypertrophy, whereby existing fibers incorporate new myonuclei via 
additional myoblast fusion (McCarthy et al., 2011). Hyperplasia, which is the formation 
of new fibers from resident satellite stem cell populations is rare after birth in most 
species, making the initial populations of fibers and myoblasts established in utero a 
crucial point in development (Bentzinger et al., 2012).  
 3 
Myogenesis 
 Skeletal muscle plays a crucial role in glucose homeostasis and the metabolic 
health of an individual, making its proper development and growth an imperative part of 
development (Felber et al., 2013; Brown, 2014). Skeletal muscle develops in stages, 
which together form a process known as myogenesis. Myogenesis begins during 
embryogenesis with the migration of somatic mesoderm progenitor cells, which 
terminally differentiate into myoblasts upon arrival at the various sites of skeletal muscle 
formation (Bentzinger et al., 2012). These cells undergo stepwise proliferation, 
differentiation, and fusion to form the polynuclear myofibers that make up skeletal 
muscle (Mitchell et al., 2002). Initial development produces primary myofibers, which 
become the scaffolding for subsequent skeletal muscle fibers. This occurs early on in 
development and is typically completed halfway through the first trimester of pregnancy 
(Sambasivan and Tajbakhsh, 2007). Late in the first trimester, secondary myofibers form 
along these initial primary fibers but, unlike primary fibers, may not run the full length of 
the developing muscle (Wilson et al., 1992). Early in the third trimester of pregnancy, 
tertiary fibers appear around the existing primary and secondary fibers, completing the 
myogenic process (Bentzinger et al., 2012). Together, these stages of myogenesis 
(Figure 1-1) establish all myofiber populations before birth in most mammals, thus fiber 
number remains static postnatal. Further growth occurs via fiber hypertrophy and requires 
the incorporation of resident myoblasts to increase myonuclear content and nuclear 
protein synthetic capacity as illustrated in Figure 1-1. 
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Myogenic regulators of skeletal muscle growth   
 Throughout the myogenic process, the transcription factors shown in Figure 1-1 
are expressed at specific stages, allowing this process to be tightly regulated. Initial 
activation of myoblasts involves the expression of two paired-box (Pax) transcription 
factors, Pax3 and Pax7, the latter of which acts as markers for these cells (Sambasivan 
and Tajbakhsh, 2007; Bentzinger et al., 2012). Pax3 is critical for the migration and 
establishment of the founder cell populations early in development, however it is not 
exclusively expressed by skeletal muscle myoblasts (Bentzinger et al., 2012). 
Alternatively, Pax7 is exclusive to myoblast populations and is responsible for 
establishing satellite cell pools and secondary fibers during the later stages of 
development and is one of the preferred markers for myoblast populations after birth 
along with myogenic factor 5 (myf5) (Seale et al., 2000; Soto et al., 2017). These pools 
of satellite cells are normally quiescent after birth acting as a reserve population capable 
of proliferating after injury regenerating muscle in a process known as hypertrophy 
(Morgan and Partridge, 2003). Terminal differentiation of myoblasts requires the 
sequential expression of a series of transcription factors belonging to the basic-Helix-
Loop-Helix (bHLH) family: myogenic differentiation factor 1 (myoD), myf5, and 
myogenin (Molkentin et al., 1995; Soto et al., 2017). Early in development, 
dermomyotome cells mature into a primitive muscle structure known as the myotome, 
which expresses high levels of myf5 followed by increased levels of myoD, marking 
them as active muscle stem cells and initiating the transformation from stem cell to 
muscle progenitor cells (Rudnicki et al., 1993; Bentzinger et al., 2012). The initial 
expression of myf5 within these cell populations is typically coincident with the 
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expression of Pax7 and proliferating cell nuclear antigen (PCNA) (Yates et al., 2014). 
This expression profile marks these progenitor cells as active myoblasts destined for 
proliferation and differentiation (Punch et al., 2009; Bentzinger et al., 2012). Terminal 
differentiation of myoblasts during late gestation and postnatal begins with the onset of 
myoD expression committing these myoblasts to differentiation (Brown, 2014; Yates et 
al., 2014). As myogenin expression then increases, myoblasts begin to fuse and form the 
myofibers that comprise skeletal muscle (Brown, 2014; Yates et al., 2014). Increased 
myogenin expression causes differentiated myoblasts and myofibers to begin expressing 
the type III intermediate filament known as desmin, which is responsible for the 
structural development of the contractile unit of skeletal muscle called the sarcomere 
(Paulin and Li, 2004). Both desmin and myogenin continue to be expressed by fetal 
skeletal muscle throughout the gestational period and in postnatal skeletal muscle, 
marking the continued fusion of myoblasts and myonuclear accumulation of myofibers 
(Andrés and Walsh, 1996; Paulin and Li, 2004; Brown, 2014). Newly formed fibers also 
begin to express myosin heavy chain (MyHC) isoforms, marking them as functional units 
capable of contractile motion (Brown, 2014). MyHC help to further classify the muscle 
fiber type and function within heterogeneous populations present in most skeletal 
muscles, as discussed in the next section (Yates et al., 2016). Together, these 
transcription factors and structural proteins serve as biomarkers for distinct stages of the 
myogenic progression of myoblasts during development and postnatal during 
hypertrophy (Figure 1-1). 
Skeletal muscle growth late in gestation and postnatal must rely on existing 
myoblast populations that reside adjacent to the muscle fibers and facilitate myofiber 
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hypertrophy (Allen et al., 1979; Yates et al., 2014). During proliferation, a sub-population 
of myoblasts does not differentiate or fuse to form fibers, instead becoming populations 
of satellite cells, quiescent skeletal muscle stem cells (Morgan and Partridge, 2003). 
These are present adjacent to muscle fibers between the sarcolemma and the endomysium 
throughout the lifespan of the organism (Yates et al., 2014; Soto et al., 2017). Upon 
injury, upregulation of muscle growth, mechanical activities such as exercise, or cell 
death, satellite cells may become activated. Most newly-activated satellite cells then 
proliferate and differentiate before fusing with existing muscle fibers, thus adding nuclei 
and increasing protein synthesis capacity (Anderson et al., 2006; Brown, 2014). A subset 
remains Pax7-positive/ myoD- negative and re-establish satellite cell populations in a 
process known as self-renewal. Thus, populations of satellite cells are maintained by 
asymmetric divisions and stored within the stem cell niche of the muscle itself, providing 
the mechanism for growth of skeletal muscle fibers (Zammit et al., 2004; Jones and 
Wagers, 2008; Yates et al., 2014). Myoblasts that commit to differentiation demonstrate 
an increase in myoD expression (Bismuth and Relaix, 2010). High levels of myoD cause 
myoblasts to exit the cell cycle, allowing most of the cells to differentiate (Zammit et al., 
2004; Brown, 2014). Subsequent upregulation of myogenin by myoD induces terminal 
differentiation, whereby myoblasts become capable of fusing with myofibers (Brown, 
2014; Yates et al., 2014; Soto et al., 2017). These two mechanisms allow for the 
maintenance of the muscle stem cell pool, while also maintaining a readily available 
source of satellite cells for muscle growth. The number of satellite cells present typically 
decreases with age, making the proper development and size of initial populations crucial 
to future skeletal muscle growth capacity (Morgan and Partridge, 2003; Brown, 2014). 
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Perturbations in the establishment of this population during fetal development will have 
lifelong negative consequences for muscle mass and the metabolic health of the 
individual.  
Skeletal Muscle Fiber Types, Metabolic Phenotypes, and Relative Abundances 
 Skeletal muscle in mammalian species have heterogeneous populations of skeletal 
muscle fibers consisting of four different types, each with their own metabolic 
phenotypes and contractile characteristics (Spangenburg and Booth, 2003; Yates et al., 
2016). Fiber type categories are defined by their metabolic phenotypes, twitch speed, and 
strength of contraction upon stimulation (Schiaffino and Reggiani, 2011; Brown, 2014). 
The proportions of fiber types within a muscle group can change over time based on the 
influence that the environment or other extrinsic factors have on the metabolic, or 
functional, demand of the muscle (Schiaffino and Reggiani, 2011; Yates et al., 2016). 
Fiber types are identified by MyHC isoforms that are indicative of the fibers metabolic 
activity, which can be broadly classified as either fast or slow twitch (Spangenburg and 
Booth, 2003; Yates et al., 2016). Type I skeletal muscle fibers are the slow-twitch fiber 
found throughout the body. These fibers are characterized by their red color due to the 
high content of myoglobin and can be identified by expression of the MyHC-I isoform 
(Schiaffino and Reggiani, 2011; Yates et al., 2016). Type I fibers exhibit high rates of 
oxidative metabolism, increased mitochondria. and myoglobin content, larger nerve 
terminals and motor endplate areas, a less developed sarcoplasmic reticulum, and higher 
cytosolic free calcium (Schiaffino and Reggiani, 2011; Wang and Pessin, 2013). These 
fibers favor oxidative phosphorylation as their primary metabolic pathway and, as their 
name implies, contract slowly and generate less mechanical force relative to other fiber 
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types (Spangenburg and Booth, 2003). Type I fibers are more fatigue resistant due to a 
greater content of mitochondria and thicker Z lines, which mark the boundaries of 
individual sarcomeres where thin actin fibers attach (Schiaffino and Reggiani, 2011).  
Type II fast-twitch fibers can be delineated into three subgroups, which are Type 
IIa, IIx, and IIb (Wang and Pessin, 2013). Type IIa fibers represent an intermediary 
population between Type I and the other Type II fibers. These fibers are anatomically red 
in color and maintain a higher content of mitochondria than other Type II fibers, relying 
on both oxidative and glycolytic pathways to generate energy for their contractile force 
(Schiaffino and Reggiani, 2011). Type IIa fibers can be distinguished from the other fast-
twitch types by their high levels of succinate dehydrogenase (SDH) activity, the presence 
of slow twitch motor units, and expression of MyHC-IIa (Spangenburg and Booth, 2003; 
Schiaffino and Reggiani, 2011). In pigs and rodents, Type IIb fibers are anatomically 
white in color due to the low amounts of mitochondria and myoglobin they contain. They 
express the MyHC-IIb isoform (Schiaffino and Reggiani, 2011). These fibers are defined 
as a fast-fatiguing, glycolytic populations that rely primarily on ATPase activity and 
present with low levels of SDH activity (Schiaffino and Reggiani, 2011). They are 
predominantly found in the lower extremities or hindlimbs and can generate a large 
contractile force. They are quick to fatigue due to the low abundance of myoglobin and 
capillary content (Spangenburg and Booth, 2003; Wang and Pessin, 2013). Humans, 
cattle, sheep, and most other non-litter bearing mammals express the mRNA transcript 
for Type IIb myosin but cannot produce the MyHC-IIb protein (Schiaffino and Reggiani, 
2011). Type IIx fast-twitch fibers are an intermediary population of fibers that are instead 
expressed by these mammals (Schiaffino and Reggiani, 2011). These fibers are 
 9 
anatomically white and rely on glycolytic metabolism to generate energy for contractile 
force (Larsson et al., 1991). They have contractile shortening velocities similar to Type 
IIa fibers, but present with less of ATPase and SDH activity and less resistance to fatigue 
relative to Type IIa fibers (Larsson et al., 1991). Type IIx fibers are identified by their 
expression of MyHC-IIx (Schiaffino and Reggiani, 2011). In addition to morphological 
and contractile differences fiber types can also be categorized by their metabolic 
phenotypes. Type I fibers demonstrate the greatest rate of insulin-stimulated glucose 
uptake making them the most insulin-sensitive of the fiber types (Yates et al., 2016). 
Type IIx fibers demonstrate the lowest insulin-stimulated glucose uptake rates with Type 
IIa fibers representing an intermediate population between Type I and Type IIx myofibers 
(Yates et al., 2016). 
Skeletal Muscle Glucose Metabolism 
Insulin regulation of skeletal muscle glucose utilization 
Skeletal muscle accounts for approximately 40% of total body mass in most 
mammals but it is responsible for upwards of 65% of total glucose consumption and 85% 
of insulin-stimulated glucose metabolism (Felber et al., 2013; Brown, 2014). Glucose is 
the primary source for energy production within skeletal muscle, and the maintenance of 
homeostatic levels is primarily facilitated by insulin-sensitive skeletal muscle (Mizgier et 
al., 2014). Systemic glucose consumption is regulated in part by the action of insulin, 
with increased circulating levels associated with higher rates of glucose uptake into 
skeletal muscle (Leney and Tavaré, 2009). Increased circulating blood glucose stimulates 
the production and secretion of insulin from pancreatic β-cells, leading to inhibition of 
hepatic gluconeogenesis and stimulation of glucose uptake by skeletal muscle for 
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utilization or storage (Aronoff et al., 2004). Changes in uptake rates are facilitated by 
insulin-dependent translocation of GLUT-4 transporters expressed by skeletal muscle, 
which rapidly translocate from the cytoplasm to the plasma membrane following insulin 
stimulation  (Limesand et al., 2007; Leney and Tavaré, 2009; Pinto-Junior et al., 2018). 
Skeletal muscle also expresses low levels of GLUT-1 transporters, which are 
ubiquitously expressed throughout the body and operate in an insulin-independent 
manner (Ebeling et al., 1998; Limesand et al., 2007). 
Metabolic pathways for glucose utilization 
 Beginning in late gestation, increased blood glucose levels in the body lead to the 
release of insulin, stimulating uptake of glucose by skeletal muscle (Hay et al., 1988). 
After uptake, glucose can be utilized by a number of different metabolic pathways shown 
in Figure 1-2. The relative activity of each pathway is dependent on the fiber type 
composition of the muscle. Upon entry into the cell, glucose is converted to the metabolic 
intermediate glucose-6-phosphate, which is then utilized via one of three major pathways 
(Jensen and Richter, 2012). Initial formation of Glucose-6-phosphate (G-6-P) is mediated 
by the enzyme Hexokinase II (HK2), an irreversible step in skeletal muscle (Petersen and 
Shulman, 2002; Jensen and Richter, 2012). G-6-P can be stored as the polysaccharide 
glycogen, providing the muscle with stores of energy that can be rapidly mobilized and 
utilized later. Glucose utilized for immediate metabolization will undergo the process of 
glycolysis. Glucose within this pathway is metabolized via a series of enzymatic 
interactions to two 3-carbon pyruvate molecules (Bouché et al., 2004). This process 
generates a relatively small amount of ATP and NADH (Bouché et al., 2004). Under 
aerobic conditions, pyruvate will enter into the mitochondria where it is utilized in the 
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TCA cycle to generate large amounts of NADH and FADH2. These high-energy electron 
carriers are then utilized by the electron transport chain for oxidative phosphorylation 
(Nelson et al., 2008). The process of oxidative phosphorylation is more time consuming 
than glycolysis, however it represents a much more efficient use of glucose by producing 
approximately 36 net ATP per glucose molecule compared to the approximately 2 net 
ATP produced by glycolysis (Nelson et al., 2008). Under nutrient poor conditions such as 
those experience by a PI-IUGR fetus, a large amount of pyruvate will instead be 
metabolized into lactate (Bouché et al., 2004). Unlike glucose, lactate can then be 
secreted by skeletal muscle to help maintain energy substrate levels within the body 
(Bouché et al., 2004). Lactate excreted from skeletal muscle can travel to the liver, where 
it is reformed into glucose via gluconeogenesis in a process called the Cori cycle (Cori, 
1931). Lactate can also be utilized by cardiac muscle as a source of energy under nutrient 
or oxygen restricted conditions (Kemppainen et al., 2002). A reduction in glucose 
oxidation coincident with an increase in the less efficient glycolytic lactate production is 
commonly associated with increases in adrenergic and inflammatory activity. It is also a 
characteristic of individuals with metabolic syndrome (Bouché et al., 2004; Limesand et 
al., 2007; Cadaret et al., 2017). 
Metabolic regulation by insulin and IGF-I pathways 
 Insulin is the primary regulator of blood glucose concentrations. This protein 
hormone is secreted by the β cells located in the islets of Langerhans within the pancreas 
(Fu et al., 2013). Pancreatic β cells sense changes in blood glucose concentrations and 
release insulin in corresponding amounts to maintain homeostatic levels within the blood. 
Tissues and organs with high energy requirements, such as skeletal muscle rely on 
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glucose as their primary source of energy and skeletal muscle stores it as glycogen for 
rapid metabolism during periods of high energy output (Horowitz et al., 2001; Mizgier et 
al., 2014). The insulin signaling cascade for skeletal muscle is shown in Figure 1-3. First, 
insulin binds to its tyrosine kinase receptor, leading to the phosphorylation of the 
downstream docking proteins, insulin receptor substrates (IRS) (Krook et al., 2000). IRS-
1 and IRS-2 are the primary types found in skeletal muscle (Krook et al., 2000; Boucher 
et al., 2014). Their phosphorylation by IR leads to the activation of the key signaling 
mediator phosphatidylinositol 3-kinase (PI3K) (Krook et al., 2000; Sarbassov et al., 
2005). PI3K is responsible for the transmitting activation signals of multiple pathways 
involved in glucose transport and metabolism within skeletal muscle. The canonical 
PI3K-mediated pathway is the activation of 3-phosphphoinositide-dependent protein 
kinase 1 (PDK-1) and its subsequent phosphorylation of the AGC protein kinase family 
including Akt1, p70 ribosomal S6 kinase (S6K), and protein kinase C (PKC) (Pearce et 
al., 2010). Phosphorylation of Thr308 leads to the partial activation of Akt1, which is a 
key mediator of metabolism within skeletal muscle (Sarbassov et al., 2005). This initial 
phosphorylation leads to the translocation of Akt1 to the plasma membrane (Dan et al., 
2016) where further activation occurs by the additional phosphorylation of a serine 
residue (S437) by the mammalian target of rapamycin (mTOR) complex-2 (Sarbassov et 
al., 2005; Dan et al., 2016). Activation of Akt inhibits protein degradation by inactivating 
forkhead box O (Foxo) via phosphorylation and also stimulates glycogen and protein 
synthesis within skeletal muscle (Sano et al., 2003; Boucher et al., 2014). Akt also 
stimulates glucose uptake via activation of the mammalian target of rapamycin complex 1 
(mTORC1) and increases lipolysis via phosphorylation of peroxisome proliferator 
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activated receptor gamma coactivator 1-alpha (PGC-1⍺) (Takaishi et al., 1999; Sano et 
al., 2003; Düvel et al., 2010; Boucher et al., 2014).  
Insulin-like growth factors (IGF-I, IGF-II) along with growth hormone are the 
primary mediators of tissue growth and differentiation (Dupont and LeRoith, 2001; 
Boucher et al., 2010). However, studies have demonstrated that these are pleiotropic 
hormones with differing tissue-specific effects (Baker et al., 1993; Westwood et al., 
2001). Similar to insulin, binding of IGF to their tyrosine receptor complexes leads to the 
activation of downstream signaling cascades, beginning with the phosphorylation of IRS, 
which then activates the PI3K-Akt1 pathway (Boucher et al., 2010). Although they utilize 
similar pathways as insulin downstream of receptor binding, IGF-I and II stimulate a 
wide range of cellular functions associated with growth and differentiation distinct from 
those of insulin (Coolican et al., 1997; Boucher et al., 2010). IGF-II is implicit in 
development and growth of the placenta, and IGF-I concentrations in fetal blood are 
directly correlated with in utero growth and birthweight (Brice et al., 1989; Ogilvy-Stuart 
et al., 1998). However, the downstream activation of mTORC1 and FoxO3 mediated 
pathways is still achieved by IGF-receptor binding. This elicits insulin-like effects on 
protein cycling and glucose metabolism, suggesting that IGFs work synergistically with 
insulin (Di Cola et al., 1997). Normal signal transduction of insulin and IGF pathways 
(Figure 1-3) is crucial for fetal skeletal muscle growth, fetal development, and 
metabolism (Rosenthal and Cheng, 1995; Thorn et al., 2011).  
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The Immune System 
Hematopoiesis and Fetal Development 
 Like myogenesis, the development of the immune system is a highly-ordered 
process that occurs in progressive stages throughout gestation (Pagenkemper and 
Diemert, 2014). Hematopoetic stem cells (HSC) begin developing in the yolk sac early in 
embryogenesis, with the first functional cells appearing late in the first trimester of 
pregnancy (Mikkola et al., 2006). The definitive origins of HSC populations remains 
unclear, but functional populations can be detected within the yolk sac, 
aortagonadmesonephros region (AGM), and placenta by the end of the first trimester 
(Ciriza et al., 2013). The placenta plays a critical role in the development of HSC by 
facilitating rapid expansion and even in situ generation of new cells (Mikkola et al., 
2006). This occurs during mid-gestation in mice with an almost 15-fold increase in HSC 
numbers compared to the AGM populations (Mikkola et al., 2005; Mikkola et al., 2006). 
Regardless of their site of origin, the fetal liver is the main site of expansion and 
differentiation of HSC before they migrate to their respective immunological organs 
(Ciriza et al., 2013). Immunological cells and their products are scarce in early 
development to avoid premature activation and allow for these cells to mature during 
development (Ygberg and Nilsson, 2012). High intrauterine production of pro-
inflammatory cytokines can be associated with growth restriction and, if severe, abortion 
(Ygberg and Nilsson, 2012). However, both naive innate and adaptive immune cells are 
present in appreciable amounts by birth (Ygberg and Nilsson, 2012; Simon et al., 2015).  
After birth, the cells of the immune system and all of the cellular elements of 
blood arise from progenitor cells in the bone marrow termed pluripotent hematopoietic 
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stem cells (pHSC) (Janeway Jr. et al., 2001). Innate and adaptive immune responses 
depend on the activities of leukocytes, which facilitate the complex interactions between 
these two overlapping arms of the immune system. Together, these two evolutionarily 
conserved systems coordinate to protect the body from infectious agents, confer lifelong 
immunity, and serve as a robust defense to the wide range of pathogenic microorganisms 
present in the postnatal environment (Janeway Jr. et al., 2001). 
The Innate Immune Response 
The majority of cells in the innate immune system shown in Figure 1-4, arise 
from a pHSC-derivative population of progenitors known as the common myeloid 
progenitors (CMP) (Janeway Jr. et al., 2001). The skin and mucosal epithelia also provide 
an additional first line of defense against infection and are considered to be part of this 
system (Gleeson et al., 1982; Nikolovski et al., 2008). CMP-derived progenitor cells 
termed granulocyte/macrophage progenitor cells (GMP) form the entire population of 
innate immune cells with the exception of lymphoid progenitor-derived natural killer 
(NK) cells (Janeway Jr. et al., 2001). Most leukocytes within the innate immune system 
perform phagocytosis, the process of engulfing pathogens (Janeway Jr. et al., 2001). 
These are identified via cell-surface pattern recognition receptors such as the members of 
the toll-like receptor family (TLR), which serve to bridge the gap between innate and 
adaptive immune responses (Alberts et al., 2002). This group of cells is collectively 
known as phagocytes and act as a non-specific defense against pathogens via recognition 
of pathogen associated molecules (PAMP) (Alberts et al., 2002). The subpopulation of 
phagocytes known as monocyte/macrophages are involved in metabolic regulation via 
interactions with endocrine pathways involved in metabolism (Alberts et al., 2002; 
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Cadaret et al., 2017). Macrophages are tissue resident phagocytes that play a critical role 
in pathogen recognition and inflammatory modulation (Meshkani and Vakili, 2016; 
Cadaret et al., 2017). Monocytes are circulating populations of bone marrow derived cells 
that patrol the lymphatic and circulatory system (Alberts et al., 2002). After recruitment 
to sites of infection or inflammation, monocytes infiltrate tissue and become 
macrophages, leading to the combined terminology monocyte/macrophage (Alberts et al., 
2002). Together with dendritic cells (DC), monocyte/macrophages represent a critical 
link between the innate and adaptive immune systems by acting as professional antigen 
presenting cells (APCs) (Alberts et al., 2002). APC are responsible for presenting 
processed epitopes in the presence of co-signaling factors such as major 
histocompatibility complexes I and II (MHC-I/II) to naïve T-cells (Triozzi and Aldrich, 
1997; Oehler et al., 1998; Alberts et al., 2002). This MHC-I/II signaling cascade leads to 
the activation of the adaptive immune component and a conserved antigen-specific 
immune response. Monocyte/macrophage activity, TLR signaling pathways, and central 
signaling vis NF𝜿B are universal to all host’s innate defense system (Janeway et al., 
2001a). The conservation of these pathways across mammalian species, vertebrates, and 
many non-vertebrates allows research on these critical pathways to be applied to most 
species. 
The Adaptive Immune Response  
 Unlike the innate immune response, the adaptive immune system (Figure 1-4) is 
specific to particular pathogens (Alberts et al., 2002). It is responsible for the clearance of 
cells presenting processed PAMP and for long-lived protection against future infection by 
specific pathogens (Janeway Jr. et al., 2001; Alberts et al., 2002). The two major cell 
 17 
types involved in adaptive immunity are T-cells and B-cells, collectively classified as 
lymphocytes (Janeway et al., 2001b). Lymphocytes arise from the common lymphoid 
progenitor (CLP) within bone marrow where B-cell maturation also occurs (Janeway Jr. 
et al., 2001).  Alternatively, T-cells migrate to the thymus before maturation can occur 
(Zinkernagel, 1978). The differences in maturation sites give rise to the differential 
classification. The adaptive immune system relies on clonal selection (CST), a theory 
first posited in the early 1950s by Drs. Burnet and Talmage (Talmage, 1957). Mammals 
and some non-mammalian species, first generate a large and diverse population of 
lymphocytes that undergo commitment within primary lymphoid organs (Talmage, 
1957).  These cells then undergo rapid clonal expansion upon activation by a particular 
antigen specific to their cell surface receptor (Talmage, 1957; Alberts et al., 2002). Since 
its initial introduction, CST has been adapted to fit more recent findings regarding the 
response and development of lymphocytes. These include the phenomenon of somatic 
hypermutation in B-cell populations and self/non-self tolerance (Silverstein, 2002).  
 T-cell populations can be separated into two categories, which together comprise 
the cellular response of the adaptive immune system (Janeway Jr. et al., 2001). Cluster of 
differentiation 8 (CD8)-positive cells known as cytotoxic T-cells facilitate the destruction 
of infected non-self cells and contribute to the memory response (Busch et al., 1998). 
CD4-positive T-cells are called helper T-cells and can be sub-categorized by their 
cytokine expression profiles and roles within the immune system into Th1, Th2, Th17, 
and Treg populations (Zhu et al., 2010). This diverse population of cells mediates a 
number of critical functions of the immune system, such as B-cell antibody production, 
CD8+ activity, macrophage regulation, orchestration of systemic immune response, 
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suppression of the immune response, and regulation of the magnitude and length of the 
immune response (Mosmann et al., 1986; Zhu et al., 2010). Activation of naive CD4+ and 
CD8+ populations requires a co-stimulatory MHC/ T-cell receptor (TCR)-dependent 
signal from the above professional antigen-presenting cells. However, once memory cells 
have been generated, they can be directly activated by their respective antigen. Similar to 
innate immunity, the adaptive immune response is conserved across vertebrate species 
(Flajnik and Kasahara, 2010).  
Cytokines and Chemokines 
 The immune and inflammatory response is tightly regulated and diverse. Cells can 
elicit differential effects based on location within the body, type of activation signal, and 
acute vs. chronic responsivity (Janeway Jr. et al., 2001). The precision of inflammatory 
responses are controlled in large part by extracellular mediators known as cytokines and 
chemokines (Turner et al., 2014). These chemical messengers allow small numbers of 
immune cell types to mediate a diverse and complex systemic immune response (Lata 
and Raghava, 2008). Upon binding, cytokines and chemokines stimulate subsequent 
intracellular signaling mechanisms modulating acute or chronic inflammation (Lata and 
Raghava, 2008; Turner et al., 2014). Furthermore, changes in the expression profiles of 
these signaling molecules have been implicated in stress responsivity, depression and 
anxiety, and pathologies like type II diabetes and metabolic syndrome (Sassoon et al., 
1988; Vogelzangs et al., 2016; Akash et al., 2018; Yates et al., 2018).  
Cytokines are small secreted proteins that serve as the chemical messengers for 
the immune system. They have the ability to mediate systemic and local inflammation, 
hematopoiesis, and immune responsivity (Lata and Raghava, 2008). Cytokines are 
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canonically categorized as pro-inflammatory or anti-inflammatory, but recent studies 
have demonstrated that cytokines can have pleiotropic effects depending upon the target 
receptors they bind, and external co-signaling factors like glucocorticoids and growth 
factors (Al-Shanti et al., 2008; Muñoz-Cánoves et al., 2013; Morey et al., 2015). 
Generally accepted pro-inflammatory cytokines include the interleukin-1 (IL-1) family, 
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF⍺), and interferon gamma (IFN𝛾) 
(Turner et al., 2014). These cytokines signal via specific receptors that are responsible for 
signal modulation and downstream effects (Figure 1-5). The major anti-inflammatory 
cytokines are interleukin-4 (IL-4), interleukin-10 (IL-10), and the pleiotropic IL-6 
(Cassatella et al., 1993; Muñoz-Cánoves et al., 2013). Similar to the inflammatory 
cytokines, anti-inflammatory cytokines signal via specific families of receptors with 
different downstream effects based on the cell type and context of activation (Ho et al., 
1993; Nelms et al., 1999) as shown in Figure 1-5. Dysfunctional expression of cytokines 
has been implicated in the development of pathologies such as anxiety, depression, and 
type II diabetes (Vogelzangs et al., 2016; Akash et al., 2018).  
Chemokines are a conserved subset of cytokines primarily responsible for the 
recruitment of circulating effector leukocytes (Moser et al., 2004). They also play roles in 
immunological surveillance and in leukocyte development (Moser et al., 2004). 
Chemokines are categorized broadly into two groups; chemotactic or homeostatic 
(Constantin et al., 2000). Similar to cytokines, chemokines are also dual-functional and 
create increasing gradients to recruit leukocytes within circulation to their target 
(Constantin et al., 2000; Turner et al., 2014). Chemokines and chemokine receptors 
(Figure 1-5) are critical for the tissue-specific responsivity of the immune system, as well 
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as proper growth and development of tissues. (Turner et al., 2014; Quinn et al., 2017). 
The best characterized chemokine in mammals is the pro-inflammatory interleukin 8, also 
known as CXCL8 (Hammond et al., 1995). Similar to its pro-inflammatory cytokine kin, 
it signals via activation of two different G-protein coupled receptors (GPCRs), 
responsible for the recruitment of leukocytes to sites of inflammation and acts as an 
angiogenic factor in humans (Hammond et al., 1995; Heidemann et al., 2003) (Figure 1-
5). Chemokine Receptor 4 (CXCR4) and its ligand (CXCL12) have been shown to play a 
role in placental growth as well as vascular development in the growing fetus 
demonstrating the pleiotropy of these signaling molecules (Quinn et al., 2017). 
Effects of Curcumin and Systemic Stress on Cytokine Regulation of Skeletal Muscle 
 Cytokines play a critical role in the regulation of tissues and organs throughout 
the body including skeletal muscle, adipose tissue, and pancreatic β-cells (Andersson et 
al., 2001; Al-Shanti et al., 2008; Hansen et al., 2010). Cytokine activity is coordinated by 
circulating and tissue resident leukocytes and lymphocytes (Fan and Rudensky, 2016; 
Holzlechner et al., 2017). Immune cells residing within the tissue possess the ability to 
self-renew (Hashimoto et al., 2013), and differential expression of surface markers 
delineate them from circulating immune cells, which are bone marrow derived 
(Hashimoto et al., 2013). Meshkani & Vakili (2016) reviewed the literature showing that 
tissue resident macrophages contribute to metabolic homeostasis and that abnormal 
population profiles are associated with development of metabolic syndrome and type II 
diabetes. 
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Tissue Resident Macrophages 
 A review by Martinez & Gordon (2014) concludes that tissue resident 
macrophages are dynamic cells capable of differential activation depending on systemic 
and local signals. Resident macrophages are categorized into two main phenotypes shown 
in Figure 1-6. M1 macrophages are classically activated by IFN𝛾, Lipopolysaccharide 
(LPS), TNF⍺, or granulocyte macrophage colony-stimulating factor (GM-CSF) (Chow et 
al., 1999; Hansen et al., 2008; Kayagaki et al., 2013). TLR4-MyD88 signaling pathways 
or inflammasome activation within these cells stimulates production of inflammatory 
factors including TNF⍺, IL-6, IL-1β, CCL2, and CCL10 (Kayagaki et al., 2013; Martinez 
and Gordon, 2014). M2 macrophages are considered to be alternatively activated by IL-4, 
IL-10, glucocorticoids, and TLR signaling (Sironi et al., 2006). This population can be 
further classified by activation signal and downstream effects into either M2a (IL-4 
activated), b (TLR/IgG/Inflammasome complex activated), or c (IL-10 and 
glucocorticoid activated) groups (Edwards et al., 2006; Sironi et al., 2006). Regardless of 
initial activating signal, cells are associated with a predominantly anti-inflammatory 
response. M2 populations are unique in their ability to recognize and respond at the 
systemic level, while also being responsible for the local resolution of the inflammatory 
response. It should be noted that these M0/M1/M2 macrophage phenotypes are dynamic 
(Lavin et al., 2014). These classifications represent a snapshot of populations in a 
constant state of flux as they respond to systemic and local signals during development 
and after maturation (Lavin et al., 2014; Martinez and Gordon, 2014).  
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Cytokine Regulation of Skeletal Muscle 
  Skeletal muscle growth, development, and function are regulated in part by 
cytokine signaling (Spangenburg and Booth, 2003; Al-Shanti et al., 2008; Muñoz-
Cánoves et al., 2013). Recent studies in our lab demonstrate that cytokines affect both 
insulin signaling and insulin-independent glucose metabolism within skeletal muscle 
(Cadaret et al., 2017).  Previous research demonstrates that skeletal muscle is capable of 
secreting cytokines and growth factors in response to tissue injury, exercise, and other 
stimuli (Pedersen and Febbraio, 2008). IL-6, TNF⍺, and IGF-I secreted by skeletal 
muscle have since been recognized as myokines and represent a source of muscle growth 
and metabolic regulation (Pedersen and Febbraio, 2008; Henningsen et al., 2010; 
Schnyder and Handschin, 2015). Thus, skeletal muscle is a highly metabolic endocrine 
organ capable of secreting a number of myokines with autocrine, paracrine, and 
endocrine effects. Two multifunctional cytokine/myokines most commonly associated 
with the regulation of skeletal muscle are TNF⍺ and IL-6 (Al-Shanti et al., 2008).  
TNF⍺ is a pleiotropic cytokine with abnormal expression involved in 
inflammatory skeletal muscle disorders and insulin resistance, and normal expression 
essential for proper skeletal muscle development and growth (Al-Shanti et al., 2008; 
Tüzün, et al., 2006). Abnormal TNF⍺ expression is commonly associated with the 
pathology of type II diabetes, muscle wasting, and pro-inflammatory responses in skeletal 
muscle (Li and Reid, 2000; Tüzün et al., 2006; Akash et al., 2018). Skeletal muscle 
expresses tumor necrosis factor receptor 1 (TNFR1) and TNFR2 (Hsu et al., 1996). Most 
inflammatory effects of TNF⍺ are due to activation of the NF𝜿B and JNK1 pathways by 
TNFR1 signaling cascades (Figure 1-6), leading to the induction of inflammation, 
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apoptosis, autophagy, and insulin resistance (Li and Reid, 2000; Plomgaard et al., 2005; 
Yang et al., 2015). Activation of TNFR1 leads to the recruitment of adaptor proteins such 
as tumor necrosis factor receptor-associated factors  (TRAF), tumor necrosis factor-
associated death domain (TRADD), and receptor interacting serine/threonine kinases 
(RIPK) (Hsu et al., 1996). These adaptor proteins activate IKK, which induces NF𝜿B, 
JNK1, and autophagy-associated pathways (Hsu et al., 1996; Criollo et al., 2010; Ting 
and Bertrand, 2016). NF𝜿B and autophagy-associated pathway activation by TNFR1 is 
dependent on TRAF2 (Puimège et al., 2014; Yang et al., 2015). Other downstream 
pathways of TNFR1 affecting apoptosis and protein metabolism in skeletal muscle are 
TRAF2-independent, signaling instead via TRADD-mediated pathways (Hsu et al., 1996; 
Guttridge et al., 1999) The activation of NF𝜿B by TNF⍺ is context-dependent within 
skeletal muscle and is involved in the regulation of cell survival and growth (Mourkioti 
and Rosenthal, 2008a). TNFR1-mediated activation of the JNK1/AMPK pathways via 
TRAF2 has similarly been shown to increase rates of mitophagy, autophagy, and reactive 
oxygen species (ROS) production (Yan et al., 2012; Yang et al., 2015). Thus, TNF⍺-
mediated pathways play a multifaceted role in the development and growth of skeletal 
muscle.  
IL-6 is another pleiotropic cytokine/myokine that binds a membrane bound 
receptor (IL6R) complexed with a homodimer of gp130 (Schroers et al., 2005). Studies 
indicate that IL6R is only expressed in its membrane-bound form on hepatocytes and 
leukocytes within the body in a classical manner (Keller et al., 2005; Wolf et al., 2014). 
However, gp130 is expressed by almost every cell within the body (Schroers et al., 2005; 
Wolf et al., 2014). These findings led to the discovery of a second soluble form of IL6R, 
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termed sIL6R (Schroers et al., 2005). sIL6R complexes first with its ligand IL-6 and then 
with a homodimer of gp130 (Schroers et al., 2005). The soluble version of IL6R is 
produced via alternative splicing of mRNA in a number of cell types including skeletal 
muscle (Keller et al., 2005; Wolf et al., 2014). This allows IL-6 to affect most cell types 
via both classical and trans-signaling (Keller et al., 2005; Wolf et al., 2014). Classical 
signaling is associated with the anti-inflammatory regenerative effects of IL6, and trans-
signaling has been implicated in the pro-inflammatory cascades that contribute to 
autoimmune disease, metabolic dysfunction, and sepsis (Rose-John, 2012; Wolf et al., 
2014; Garbers et al., 2015). Activation of both receptor types leads to the association of 
Janus kinases (JAK) JAK1 and JAK2 with gp130 (Figure 1-6) (Stahl et al., 1994). These 
recruit signal transducer and activator of transcription (STAT)-1 and STAT3 to be 
phosphorylated and translocated to the nucleus, where they up-regulate transcription of 
genes involved in the IL-6 response (Hemmann et al., 1996). Inhibition of this pathway 
occurs via negative feedback from JAK/STAT-induced suppressor of cytokine signaling-
3 (SOCS3), allowing the cell to return to its basal state (Babon et al., 2014). JAK-
mediated phosphorylation events can also activate the MAPK pathways and interact with 
the PI3K pathway (Heinrich et al., 2003), which has multifunctional effects on skeletal 
muscle. IL-6 produced during muscle contraction increases satellite cell proliferation in 
adult skeletal muscle and prevents premature differentiation in developing myocytes (Sun 
et al., 2007). However, IL-6 also interferes with IGF-1 signaling, increases age-related 
muscle atrophy, and promotes some inflammatory disorders (Bartoccioni et al., 1994; De 
Benedetti et al., 1997; Bonetto et al., 2012).  
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Curcuminoid effects on skeletal muscle growth and cytokine signaling 
Turmeric root, and its bioactive polyphenol curcumin represent a topic of 
intensive research. A review of recent research by Hewlings & Kalman (2017) 
summarizes how this extract of Curcuma longa plants may help manage inflammatory 
and oxidative conditions. The anti-inflammatory effects of curcumin have been attributed 
to its role as a NF𝜿B inhibitor (Mourkioti and Rosenthal, 2008b). The NF𝜿B pathway 
can be activated by the inflammatory cytokine TNF⍺ to suppress myogenesis and 
stimulate proteolysis promoting, loss of muscle protein (Mourkioti and Rosenthal, 
2008b). However, it also enhances satellite cell proliferation and promotes cell survival 
(Guttridge et al., 1999; Li and Reid, 2000; Mourkioti and Rosenthal, 2008b). Inhibition of 
this pathway by curcuminoids may mediate some of the detrimental effects of cytokines 
on skeletal muscle growth. 
Stress-induced modulation of cytokine expression 
 Recent work has begun to assess systemic immunological responses to different 
stressors and psychological pathologies. Reviews of this research indicate the differential 
effects of stress type and magnitude on immune function, with differences in cytokine 
secretion, antibody production, and cytokine expression pattern switching occurring in 
circulating leukocytes (Padgett and Glaser, 2003; Morey et al., 2015). Circulating 
leukocytes express glucocorticoid (GR) and catecholamine (ADR) receptors that upon 
binding modulate the function of NF𝜿B, regulating cytokine production and gene 
expression (Padgett and Glaser, 2003). Glucocorticoid (GC) binding to GR under high 
stress conditions has been shown to modulate cytokine production by suppression of 
NF𝜿B and downregulating pro-inflammatory cytokine gene expression, favoring a 
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Th2/M2 anti-inflammatory phenotype instead (Reichardt et al., 2001). However, GC also 
sensitize the innate immune system and upregulate inflammation through activation of 
the NLRP3 inflammasome (Busillo et al., 2011).  Furthermore, under periods of chronic 
stress GR levels are decreased in part due to cytokine over-stimulation of the HPA-axis 
(Liu et al., 2017). The catecholamines epinephrine (E) and norepinephrine (NE) modulate 
immune function primarily through the actions of β2 adrenergic receptors (ADRβ2) and 
the subsequent synthesis of cyclic-AMP (cAMP) (Reichardt et al., 2001). ADRβ2 
appears to be preferentially expressed on Th1/M1 pro-inflammatory immune cells in 
circulation and within tissues (Bellinger et al., 2008) Acute stimulation by 
catecholamines leads to increased expression of inflammatory cytokines but has an 
overall inhibitory effect similar to GCs (Bellinger et al., 2008). More recently, studies 
have connected stress-induced cytokine expression and inflammation to behavioral 
pathologies including anxiety and depression (Henry et al., 2008; Peng et al., 2012). 
Together, this represents a promising new avenue of research regarding stress modulated 
immunology, and its role in behavior. However, it is necessary to first understand the role 
that inflammatory cytokines play in muscle growth and metabolic health outcomes.   
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Figure 1-1. Myogenic progression markers from precursor cells to mature muscle 
fibers 
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Figure 1-2. Schematic illustrating the major pathways by which glucose is 
metabolized in skeletal muscle. 
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Figure 1-3. Schematic of the pathways activated and effects of ligand binding to 
Insulin Receptor (IR), Insulin-like Growth Factor I Receptor/Insulin Receptor 
Heterodimer (IGF-IR/IR), and Insulin-like Growth Factor I Receptor (IGF-IR) by 
Insulin, IGF-I and IGF-II. 
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Figure 1-4. Immune cell development and site of maturation from precursor cells to 
terminally differentiated populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood ADAPTIVE
CELLS
Tissues
Thymus      Bone Marrow
Lymph Node
INNATE 
CELLS
Bone Marrow
Pluripotent Hematopoietic Stem Cell (pHSC)
Common Lymphoid Progenitor (CLP)
Common Myeloid Progenitor (CMP)
Granulocyte/macrophage 
progenitor (GMP)
Granulocytes:
-Basophil
-Eosinophil
-Neutrophil
Monocyte
Dendritic Cell
Natural Killer Cell
T-Cell B-Cell
Macrophage
Treg,TH1,TH2 Maturation
Figure 4
 31 
 
Figure 1-5. Schematic of activation signals and the different effects on inflammation 
and immunoregulation of M1 and M2 macrophages. 
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Figure 1-6. Diagram of Tumor Necrosis Factor alpha (TNFA) and Interleukin 6 (IL-
6) signaling pathways and downstream effects on growth and survival in myoblasts. 
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Chapter 2: Maternofetal inflammation at 0.7 gestation in ewes 
leads to mild intrauterine growth restriction and impaired 
glucose metabolism in offspring at 30d of age. 
Abstract 
 Intrauterine growth restriction (IUGR) leads to lifelong deficits in growth of 
offspring as well as an increased risk for metabolic disorders. These effects may be due in 
part to intrinsic inflammatory system programming that occurs in response to chronic 
exposure to stress in utero. Recent studies by our lab demonstrate that maternal 
inflammation during either mid- or late-gestation induces an IUGR phenotype in fetal rats 
and sheep, respectively. Turmeric root extract and its main polyphenol component 
curcumin have antioxidant and anti-inflammatory properties. The objective of this study 
was to determine whether sustained maternal inflammation at 0.7 gestation induces fetal 
IUGR and programmed inflammatory system responses that persist in lambs at 30 days 
of age, and whether these lead to deficits in growth and metabolism. We further sought to 
determine whether these effects could be mitigated by daily oral curcumin 
supplementation of the lambs. Timed-mated Polypay ewes were injected with bacterial 
endotoxin (MI-IUGR) or saline (controls) on the 100th,104th,107th,110th, and 113th day of 
gestational age (dGA; term~145 dGA). A subset of MI-IUGR lambs received a daily oral 
supplement of curcumin mixed in piperine and corn oil (MI-IUGR+C), and all other 
lambs received the piperine/corn oil carrier only.  In MI-IUGR ewes, total white blood 
cells (WBC) decreased (P < 0.05) immediately after each injection before subsequently 
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increasing (P < 0.05). Rectal temperatures increased (P < 0.05) after each injection before 
returning to normal, demonstrating a canonical inflammatory response. Lambs were 
weaned 24 hours after birth. Birthweights of MI-IUGR lambs tended to be less (P < 0.1) 
than controls, and females tended to be lighter (P <0.1) than males. Abdominal 
circumference / body weight (BW) and cannon bone length / BW were greater (P < 0.05) 
in MI-IUGR lambs at birth indicating asymmetric growth restriction. Day30 BW of MI-
IUGR lambs was less (P < 0.05) than controls, but MI-IUGR+C BW did not differ from 
controls. MI-IUGR males tended to be lighter (P < 0.1) at 30d than males from the other 
groups. Average daily gain (ADG) was less (P < 0.05) in MI-IUGR and MI-IUGR+C 
compared to controls for males but not for females. Head circumference growth over the 
30d period was greater (P < 0.05) in MI-IUGR and MI-IUGR+C females and less (P < 
0.05) in MI-IUGR and MI-IUGR+C males compared to respective controls. Abdominal 
circumference growth was greater (P <0.05) in MI-IUGR+C females and less (P<0.05) in 
MI-IUGR+C males compared to controls. Brain weight / BW was greater (P < 0.05) in 
MI-IUGR and MI-IUGR+C males compared to control males and was greater (P < 0.05) 
in MI-IUGR males compared to MI-IUGR+C males, indicating persistent asymmetric 
growth. Glucose-stimulated insulin secretion determined by square-wave hyperglycemic 
clamp did not differ among groups. Hindlimb insulin-stimulated glucose oxidation was 
less (P = 0.01) in MI-IUGR and MI-IUGR+C compared to control hindlimbs. Hindlimb 
Insulin-stimulated glucose uptake did not differ among groups. Ex vivo primary skeletal 
muscle glucose uptake was less (P < 0.05) in MI-IUGR muscle compared to control and 
MI-IUGR+C. Ex vivo glucose oxidation was less (P < 0.05) in MI-IUGR and MI-
IUGR+C muscle compared to controls and was less (P < 0.05) in MI-IUGR lambs 
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compared to MI-IUGR+C. Insulin increased (P < 0.05) ex vivo glucose uptake and 
glucose oxidation (P < 0.05) in primary skeletal muscle in all groups. TNF⍺ increased (P 
< 0.05) glucose uptake in MI-IUGR muscle. The results of this study demonstrate that 
sustained maternal inflammation at 0.7 gestation caused fetal programming that affected 
postnatal growth and glucose metabolism of MI-IUGR offspring. Future research to 
determine what the mechanisms for inflammatory programming observed in MI-IUGR 
offspring is warranted to understand how these inflammatory system changes arise and 
contribute to the IUGR phenotype. Supplementation of curcumin in this study had 
minimal effects on deficits in growth but was able to partially improve skeletal muscle 
glucose oxidation. Further research is needed at different dosages, frequencies, and routes 
of administration, as curcumin may represent a potential treatment for improving 
metabolic outcomes in MI-IUGR offspring. 
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Introduction 
Intrauterine growth restriction (IUGR) leads to lifelong deficits in growth and 
metabolic function of offspring, which increases risk for metabolic disorders (Hales and 
Barker, 2013). Fetuses adapt to adverse in utero environments by repartitioning nutrients 
to critical organs (i.e., brain, heart, lungs) and away from skeletal muscle (Yates et al., 
2012; Yates et al., 2018). This fetal programming is beneficial in utero but leads to 
persistent reductions in muscle mass and glucose metabolism that prove detrimental to 
glucose homeostasis in offspring (DeFronzo et al., 1981). Recent studies done by our lab 
demonstrate that maternal inflammation during both mid- and late-gestation may induce 
programmed inflammatory responses that impair muscle growth and glucose metabolism 
in fetal rats and sheep (Cadaret et al., 2017; Cadaret et al., 2018). This could be due to 
altered responsiveness of skeletal muscle to cytokines and other inflammatory changes 
that disrupt insulin action and glucose metabolism (Cadaret et al., 2017; Cadaret et al., 
2018; Posont et al., 2018). Curcumin is the main bioactive polyphenol in extracts of the 
root of Curcuma longa and has anti-inflammatory and anti-oxidative properties in 
humans and animals (Hewlings and Kalman, 2017; Mariely Jaguezeski et al., 2018). The 
bioavailability of curcumin alone is relatively low in the digestive tract, but is increased 
by co-administration with piperine and corn oil (Jenkins and Fotouhi, 1990; Shoba et al., 
1998). We hypothesize that the maternal inflammation-induced fetal programming 
responses we previously observed in MI-IUGR fetuses contribute to growth and 
metabolic deficits in MI-IUGR offspring at 30d, and that supplementation with curcumin 
may mitigate their effects. Therefore, the objective of this study was to determine if 
sustained maternal inflammation induced by the administration of LPS during late-
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gestation produces MI-IUGR offspring and fetal programming responses that impair 
growth and metabolism at 30 days after birth. We further sought to determine if daily oral 
supplementation of curcumin could mitigate the effects on growth and metabolism in MI-
IUGR offspring. 
Materials and Methods 
Animals and Experimental Design 
 All procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Nebraska-Lincoln. Studies were performed at the 
University of Nebraska-Lincoln Animal Science Complex, which is an AAALAC 
International accredited institution. Timed-mated Polypay ewes were treated (i.v.) with 
saline (control, n = 8) or 0.1 µg/ kg BW of bacterial lipopolysaccharide (LPS; n = 12; E. 
coli O55:B5; MilliporeSigma) in saline every third day from dGA 100 to 115 to produce 
maternal inflammation-induced IUGR (MI-IUGR) lambs. Rectal temperatures were 
recorded and complete blood counts (CBC, HemaTrue Veterinary Chemistry Analyzer, 
Heska) were performed for total and differential white blood cell (WBC) concentrations 
on blood samples collected at 0, 3, 6, 12, 24, and 48hr after each injection of LPS. After 
vaginal birth, lambs were weighed and measurements were taken for head circumference 
(HC), abdominal circumference (AC), crown-rump length (CRL), and cannon bone 
length (CB). Lambs received colostrum within 12hr of brith. After 24 ± 2 hours, lambs 
were weaned and transitioned to ad libitum milk replacer (DuMOR) prepared according 
to manufacturer recommendations. Daily intake was recorded. Lambs were weighed daily 
and body measurements were taken every week. Beginning at weaning a subset of MI-
IUGR lambs (MI-IUGR+C; n = 6) received daily oral supplement of curcumin (95% 
 38 
pure HPLC-verified; Bulk Supplements) mixed with commercial corn oil (1ml for first 
three days, and 1.5ml after until necropsy at d30 ± 2) and 20 mg/kg BW of piperine (95% 
pure HPLC-verified; Z-natural foods). All other lambs received corn oil and piperine 
carrier only. At 25 ± 2 days, indwelling catheters and a perivascular blood flow probe 
were surgically placed in hindlimb femoral arteries and veins as previously described 
(Cadaret et al., 2018). Blood samples were subsequently collected daily from an arterial 
catheter and CBC and blood gas, glucose, and lactate concentrations (ABL, ABL90 
FLEX blood gas analyzer, Radiometer) were performed. Glucose-stimulated insulin 
secretion (GSIS) and hyperinsulinemic-euglycemic clamp (HEC) studies were 
performed at day 28 ± 2 and 29 ± 2 respectively. Lambs were euthanized at 30 ± 2 days 
of age via a double barbiturate overdose. Organ weights were recorded and flexor 
digitorum superficialis muscles were isolated for ex vivo metabolic studies.  
Lamb GSIS Studies 
 β-cell function was determined using a square-wave hyperglycemic clamp 
performed at day 28 ± 2 of age in control (n = 8), MI-IUGR (n = 6), and MI-IUGR+C (n 
= 6) lambs as previously described (Yates et al., 2012; Camacho et al., 2017a). Three 
baseline samples were collected at 5-min intervals prior to an intravenous dextrose bolus 
(150mg/kg). This bolus was followed by continuous variable-rate infusion of 33% 
dextrose solution targeting a steady-state glucose concentration of ~2-fold baseline value. 
After 30 minutes of steady-state hyperglycemia three additional blood samples were 
collected at 5-min intervals. Blood collected in EDTA syringes was centrifuged (14,000 x 
g, 2min, 4ºC) to isolate plasma. Insulin concentrations were determined in duplicate via 
ELISA (Ovine Insulin, Alpco). Intra- and inter-assay CV were 14.75% and 13.11% 
 39 
respectively. Samples collected in heparin-coated syringes were analyzed for blood gas, 
glucose, and lactate using an ABL90 FLEX (Radiometer).  
Lamb Hindlimb Glucose Metabolism Studies 
 Hindlimb-specific glucose utilization and oxidation rates at baseline and during 
hyperinsulinemic euglycemic clamp (HEC) were determined in control, MI-IUGR, and 
MI-IUGR+C lambs on day 29 ± 2 of age as described previously (Cadaret et al., 2018). 
Lambs were first bolused (1mL, i.v.) with U-[14C]-glucose tracer (18.75 µCi/mL; Perkin-
Elmer) prior to constant infusion (1ml/hr). Arterial and venous blood were collected 
simultaneously at 5-min intervals (4 total draws) in heparin-coated syringes and EDTA 
syringes after 40-min of infusion. Lambs were then bolused with glucose (150mg/kg) and 
insulin (1500 mU; Humulin-R, Eli Lilly) before infusion (glucose, variable rate; insulin 
500mU/mL, 5mL/hr) to produce stead state HEC. After HEC was achieved for 2hrs, 
simultaneous venous and arterial samples were again collected at 5-min intervals as 
described above. To measure glucose oxidation, whole blood (0.3mL) was added in 
triplicate to micro-centrifuge tubes containing 2 M HCl and suspended inside a sealed 20-
mL scintillation vial containing 1 M NaOH. HCl facilitates the release of CO2 from 
blood, which is then captured by the NaOH. After a 24-hr incubation at room 
temperature, the micro-centrifuge tube was removed and UltimaGold scintillation fluid 
(Perkin-Elmer) was added to each vial. Concentrations of 14C from each blood sample 
was quantified using a Beckman-Coulter 1900 TA LC counter. Hindlimb glucose 
utilization rate was calculated as the difference in glucose concentration between arterial 
and venous samples normalized to the femoral blood flow rate and hindlimb weight at 
necropsy. Glucose oxidation rates were quantified from the difference between venous 
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and arterial 14C specific activities normalized to femoral blood flow rate and hindlimb 
weight at necropsy. The amount of glucose oxidized in nmol was calculated from blood 
14C using the specific activity of the infused radiolabeled glucose.  
Primary Skeletal Muscle Glucose Metabolism 
 Glucose uptake and oxidation was quantified in primary skeletal muscle from 
control, MI-IUGR, and MI-IUGR+C lambs as previously described (Cadaret et al., 2017). 
The flexor digitorum superficialis muscle of each lamb was collected tendon-to-tendon 
and dissected longitudinally into ~800mg strips. Isolated flexor digitorum superficialis 
muscles were washed in phosphate buffered saline (PBS; pH7.4) and pre-incubated for 
1hr at 37ºC in Krebs-Henseleit bicarbonate buffer (KHB) containing no additives (basal), 
insulin (5mU/mL Humulin-R), or tumor necrosis factor alpha (TNF⍺) (20 ng/mL; 
MilliporeSigma). Muscle strips were then washed for 20-min in zero glucose treatment-
spiked KBH. Glucose uptake was measured by incubating muscle strips in treatment-
spiked KHB containing 1 mM [3H]2-deoxyglucose (300µCi/mmol) and 1mM [14C]-
mannitol (1.25µCi/mmol) for 20min. Glucose oxidation was measured by incubation in 
treatment-spiked KHB containing [14C-U]D-glucose (0.25µCi/mmol) for 2 hrs, before 
capturing 14CO2 in 1M NaOH for 2 hrs. 
Serum Curcumin Quantification 
 Jugular blood draws were taken from MI-IUGR+C lambs 3hr after 
supplementation with curcumin every third day after birth until the HEC was performed 
at day 29 ± 2 of age. Blood collected in EDTA tubes (~1mL) was analyzed for WBC. 
Blood collected in 3mL Heparin coated tubes (~2mL) was centrifuged (3,500 x g, 15 
min, 4ºC) to isolate serum and stored at -80ºC. These samples were then sent to the 
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Proteomics and Metabolomics Facility (PMF; UNL Center for Biotechnology Core 
Facility) where the three bioactive curcuminoids curcumin, bisdemethoxycurcumin, and 
demethoxycurcumin were measured using liquid chromatography with tandem mass 
spectrometry (LC-MS/MS).  
Statistical Analysis 
All data were analyzed using the Mixed procedure in SAS (SAS Institute, Cary 
NC) with lamb as the experimental unit. In vivo and ex vivo data were analyzed for 
effects due to experimental groups, period (or incubation condition), and the interaction. 
Period/condition was treated as a repeated variable. For in vivo metabolic studies, 
samples within each period were averaged for each lamb. Similarly, technical replications 
were averaged for each lamb in ex vivo studies. Morphometric and CBC data were 
analyzed for effects due to treatment in maternal data and effects due to experimental 
groups, sex, and the interaction in neonates. All data are presented as means ± SEM. 
  
 42 
Results 
Maternal CBC Response  
 Maternal total WBC and differential WBC values for monocytes and granulocytes 
decreased (P < 0.05) by 3 hr in MI-IUGR ewes after each LPS injection before increasing 
(P < 0.05) by ~24hr and subsequently normalizing by ~72hr over the period between each 
injection (Figure 2-1A, 2-1B, and 2-1C respectively). Differential WBC for lymphocytes 
decreased (P < 0.05) by 3hr and normalized by ~24hr (Figure 2-1D) Rectal temperatures 
increased (P < 0.05) by 3hr and normalized by ~9hr (Figure 2-1E).  
Neonatal CBC Response 
 Neonatal total WBC and differential WBC values for monocytes and granulocytes 
differed (P < 0.01) by day across all groups to varying degrees (Figure 2-2A, 2-2B, 2-
2C, and 2-2D). 
Lamb Growth Metrics 
MI-IUGR (n=12) birthweight tended to be less (P <  0.1) than controls (n=8) but 
cannon bone length/bodyweight and abdominal circumference/bodyweight was greater (P 
< 0.05) than controls (Figure 2-3). In males, MI-IUGR (n=4) and MI-IUGR+C (n=3) 
bodyweight tended to be less (P < 0.1) than controls (n=3) at 30d and MI-IUGR 
bodyweight tended to be less (P < 0.1) than MI-IUGR+C males. At 30 days, abdominal 
circumference/bodyweight and cannon bone length/body weight was greater (P < 0.05) in 
MI-IUGR lambs than controls (Figure 2-4) and ADG, head circumference growth, and 
abdominal circumference growth was less (P < 0.05) in MI-IUGR and MI-IUGR+C than 
control males (Figure 2-5). In females, MI-IUGR (n=2) and MI-IUGR+C (n=3) head 
circumference growth was greater (P < 0.05) than controls (n=5) and abdominal 
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circumference growth was greater (P < 0.05) in MI-IUGR+C compared to both other 
groups (Figure 2-5). Lung weight/ bodyweight was greater (P = 0.01) in MI-IUGR lambs 
compared to controls and less (P= 0.01) in MI-IUGR+C lambs regardless of sex (Figure 
2-6A) In males, brain weight/ bodyweight was greater (P < 0.05) in MI-IUGR and MI-
IUGR+C compared to controls and greater (P < 0.05) in MI-IUGR compared to MI-
IUGR+C (Figure 2-6B).  
Glucose-Stimulated Insulin Secretion  
 GSIS studies did not reveal any significant differences between groups (Figure 2-
7). Baseline hindlimb glucose uptake and oxidation rates did not differ between groups, 
nor did plasma insulin.  
Hindlimb Glucose Metabolism 
Under HEC conditions, hindlimb insulin-stimulated glucose oxidation was less (P 
= 0.01) in MI-IUGR and MI-IUGR+C lambs compared to controls (Figure 2-8). There 
were no differences in hindlimb insulin-stimulated glucose uptake between groups. 
Ex Vivo Primary Skeletal Muscle Metabolism 
 Glucose uptake by primary skeletal muscle from MI-IUGR lambs was less (P < 
0.05) than that of control and MI-IUGR+C muscle (Figure 2-9A). MI-IUGR skeletal 
muscle glucose uptake was increased (P < 0.05) by incubation with TNF⍺ compared to 
basal. Incubation with insulin increased glucose uptake in all groups. In all media, 
glucose oxidation rates were less (P < 0.05) in MI-IUGR and MI-IUGR+C muscle 
compared to control muscle and in MI-IUGR skeletal muscle compared to MI-IUGR+C 
skeletal muscle (Figure 2-9B).  Insulin increased glucose oxidation rates in all groups. 
 44 
Discussion 
 The results of this study demonstrate that sustained maternal inflammation during 
late gestation produces IUGR and fetal programming responses in skeletal muscle that 
impair glucose metabolism in offspring at 30d. It further demonstrates that 
supplementation of curcumin has minimal effects on growth deficits but may be able to 
mitigate the changes in skeletal muscle glucose oxidative metabolism. MI-IUGR lambs 
were smaller at birth than their control counterparts but had greater abdominal 
circumference and cannon bone length to body weight ratios than controls, which is 
indicative of asymmetrical fetal growth. At 30d, MI-IUGR lambs had greater abdominal 
circumference and cannon bone length by bodyweight ratios and MI-IUGR males had 
lower bodyweights compared to both control and MI-IUGR+C lambs, which indicate that 
asymmetrical growth continues after birth in MI-IUGR lambs but is tempered by 
supplementation with curcumin. Growth rates in males were slower in MI-IUGR lambs 
receiving curcumin or placebo compared to controls, but growth rates in females did not 
differ among groups. Consistent with asymmetrical growth, the brain and lung weights 
relative to BW in all MI-IUGR males were greater than controls, but this size differential 
was tempered when MI-IUGR were supplemented with curcumin. We previously found 
that chronic maternal inflammation during late gestation leads to asymmetric fetal growth 
rates (Cadaret et al., 2018), and the morphometric and organ spring differences observed 
in the present study show that these intrinsic growth characteristics persist in the neonate. 
Interestingly, female growth characteristics appeared to be less affected than males. Such 
differences between sexes are not unprecedented as, recent studies have reported 
differences between sexes in growth during early life in humans (Alur, 2019) and IUGR 
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lambs (Hunter et al., 2015). This could represent a survival advantage in females after 
periods of maternal stress and inflammation, but more research is warranted to 
understand why this sex-specific dimorphism occurs and how it mitigates growth deficits 
after intrauterine growth restriction in females.  
Supplementation with curcumin had minimal effects on deficits in growth 
characteristics in this study. If programmed inflammatory responses are indeed 
contributing to the asymmetrical growth observed in MI-IUGR lambs, then this minimal 
effect on growth may be due to the anti-inflammatory properties of curcumin. The 
observed minor improvements and mitigation of asymmetrical growth characteristics in 
this study could be due to curcumins ability to reduce inflammatory signaling pathways 
in peripheral tissues and reduce circulating inflammatory cytokines (Hewlings and 
Kalman, 2017). This would mitigate the effects of some of these inflammatory 
programming responses on peripheral tissue growth characteristics and temper the growth 
deficits as we observed in this study. This effect may instead be due to curcumins ability 
to reduce serum free fatty acids, decrease blood glucose, and modulate the expression of 
genes involved in lipoprotein metabolism in patients that suffer from metabolic 
syndrome, which could lead to the alleviation of some of the nutrient repartitioning 
inherent in asymmetrical growth (Na et al., 2013; Hewlings and Kalman, 2017). Thus, the 
observed improvements in growth could instead be due to shifts in fatty acid metabolism 
and reductions in serum free fatty acids which has been shown to improve insulin 
resistance (Na et al., 2013), rather than alleviating the inflammatory responses that 
contribute to the initial deficits in metabolism. This would instead involve shifts away 
from the nutrient repartitioning responses that contribute to asymmetrical growth in 
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IUGR-offspring by modulating fatty acid metabolism and transport allowing for some 
minimal improvements in growth as we observed. Further research is clearly warranted to 
determine how curcumin is able to mitigate some of the deficits in growth observed in the 
current study and what mechanism are involved.  
 Glucose-stimulated insulin secretion was neither impaired by MI-IUGR 
programming, nor improved by curcumin supplementation. These findings contrast with 
the results of our fetal study using the same model for IUGR and indicate that late-
gestation sustained maternal inflammation induces conditions that suppress β-cell 
function in utero but not fetal programming that impairs β-cell functional capacity after 
birth. Previous studies using placental insufficiency to create IUGR have demonstrated 
that impaired β-cell function and islet development is due to hypercatecholaminemia in 
IUGR fetuses (Macko et al., 2016; Boehmer et al., 2017). These β-cell deficits persist in 
the PI-IUGR born lamb (Camacho et al., 2017a). Adrenergic function was not measured 
in the present study, but we would not expect changes in adrenergic function in a model 
of maternal inflammation as these effects are due to a sustained inflammatory response 
and are not likely to illicit the fetal stress response and hypercatecholaminemia observed 
in models of placental insufficiency.  Sustained MI-induced fetal programming did affect 
glucose metabolism by altering hindlimb specific glucose oxidation and skeletal muscle 
glucose utilization and oxidation. Fetal programming induced by our model may not be 
detrimental to β-cell function as it failed to maintain dysfunction at measurable levels in 
the absence of the restricted uterine environment, unlike the maternal hyperthermic 
model for IUGR (Camacho et al., 2017a). Previous studies demonstrated that adrenal 
demedullation improves functional insulin secretion in IUGR fetuses, but does not 
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completely alleviate the metabolic deficits caused by IUGR and in fact further impairs β-
cell development (Davis et al., 2015; Macko et al., 2016). Thus, fetal programming 
responses to maternal inflammation likely affect peripheral tissue responsiveness to 
insulin rather than inducing β-cell dysfunction proper.  
Insulin-stimulated hindlimb glucose oxidation rates were impaired in MI-IUGR 
lambs compared to controls demonstrating the postnatal persistence of fetal programming 
responses that change insulin responsivity of glucose metabolism and contribute to 
metabolic dysfunction. Ex vivo studies showed that skeletal muscle that glucose uptake 
was diminished in MI-IUGR neonates but was recovered by daily oral supplement of 
curcumin. Skeletal muscle glucose oxidation was also impaired in MI-IUGR lambs but 
was partially recovered by curcumin supplementation. These disparities among 
experimental groups were observed under both basal and insulin-stimulated conditions. 
Stimulation with TNF⍺ increased glucose uptake by MI-IUGR muscle but did not have 
an effect on glucose uptake in skeletal muscle from either of the other two groups. Our 
previous studies demonstrated that IUGR myoblasts and skeletal muscle have intrinsic 
adaptations in inflammatory signaling pathways (Posont et al., 2018; Yates et al., 2018), 
and TNF⍺ increases glucose uptake by acting as an insulin mimetic (Bach et al., 2013) 
contributing to the pathogenesis of Type II diabetes (Plomgaard et al., 2005; Akash et al., 
2018). Increased glucose uptake when MI-IUGR skeletal muscle was stimulated with 
TNF⍺ may reflect a similar condition. Regardless, it demonstrates that MI-IUGR skeletal 
muscle responds differently to stimulation with TNF⍺. The recovery of normal glucose 
uptake rates and improved oxidation rates associated with curcumin supplementation 
suggest that curcumin mitigates deficits in skeletal muscle glucose metabolism. This may 
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be due to its ability to promote insulin sensitivity in peripheral tissues possibly due to the 
anti-inflammatory effects of this polyphenol, which could suppress inflammatory 
pathways that have been previously implicated in the development of insulin resistance 
(Plomgaard et al., 2005; Chen et al., 2015).   
From the results of this study, we conclude that sustained maternal inflammation 
during late gestation restricts fetal growth, yielding IUGR at birth. MI-IUGR lambs 
develop intrinsic fetal programming that reduces growth and skeletal muscle glucose 
metabolism at 30 days of age. These programmed changes likely contribute to the deficits 
in growth and metabolic dysfunction observed in this and other studies. Females in this 
study exhibited similar growth rates among all experimental groups, which may indicate 
a possible survival advantage in this model of IUGR, as evidenced by their neonatal body 
morphometrics compared to males. The mechanistic explanation for this sex-specific 
advantage, however, is not clear from this study. The fetal programming response to 
sustained maternal inflammation during late gestation did not produce the β-cell 
dysfunction observed in other IUGR models or in fetal studies with this model, perhaps 
due to a lack of fetal hypercatecholaminenia. Fetal programming to maternal 
inflammation did produce changes in skeletal muscle responsivity to insulin that was 
consistent with prenatal observations. Primary skeletal muscle from MI-IUGR lambs 
demonstrated consistent deficits in glucose uptake and oxidation that were improved by 
daily oral curcumin. Additionally, MI-IUGR skeletal muscle glucose uptake increased in 
response to TNF⍺, suggesting that inflammatory programming previously observed in the 
MI-IUGR fetus modulates skeletal muscle responsivity to cytokines. This represents one 
example of a possible inflammatory adaptation that confers a survival advantage in utero 
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but contributes to metabolic dysfunction after birth. Future research to determine the 
mechanisms for inflammatory programming observed in MI-IUGR is warranted to 
understand how they contribute to the IUGR metabolic phenotype. Supplementation of 
curcumin in MI-IUGR offspring had minimal benefit on growth and whole-body 
metabolism of lambs during the first 30 days of life. However, it appeared that curcumin 
was able to improve glucose uptake and oxidation rates in skeletal muscle. Although 
these results are encouraging, further research at different dosages, frequency, and routes 
of administration will better determine the efficacy of curcumin as a treatment for 
improving outcomes in MI-IUGR offspring.  
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Figure 2-1. Total (A) and differential white blood cell counts for Lymphocytes (B), 
Monocytes (C), and Granulocytes (D) and rectal temperatures (E) of pregnant ewes 
injected with saline (control; n=8) or bacterial endotoxin (MI-IUGR; n=12) every 
three days from 100-115 dGA. Arrows indicate injection time points and x-axis 
values are time (hr) after first injection. * Mean differs (P < 0.05) from the mean of 
the control group. 
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Figure 2-2. Total and differential (Granulocyte, Monocyte, and Lymphocyte) white 
blood cell counts for neonates.  
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Figure 2-3. Lamb birthweight (A), measures of cannon bone length (B) and 
abdominal circumference (C) by birthweight respectively in control (n=8; males=3, 
females=5) and MI-IUGR (n=12; males=7, females=5) at birth. MI-IUGR lambs 
weighed less than controls at birth, and demonstrated asymmetrical growth 
restriction.  
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Figure 2-4. Bodyweight (A), cannon bone length by bodyweight (B) and abdominal 
circumference by bodyweight (C) at day30 in control (n=8; males=3, females=5), 
MI-IUGR (n=6; males=4, females=2), and MI-IUGR+C (n=6; males=3, females=3) 
neonates. MI-IUGR lambs weighed less than control and MI-IUGR+C lambs and 
demonstrated asymmetrical growth characteristics.  
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Figure 2-5. Average daily gain (A), Head circumference growth (B), and Abdominal 
circumference growth (C) of control (n=8; males=3, females=5), MI-IUGR (n=6; 
males=4, females=2), and MI-IUGR+C (n=6; males=3, females=3) neonates.a,b,c 
Means with differing superscripts differ. 
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Figure 2-6. Brainweight by bodyweight (A) and Lung by bodyweight (B) of control 
(n=8; males=3, females=5), MI-IUGR (n=6; males=4, females=2), and MI-IUGR+C 
(n=6; males=3, females=3) lambs. Lung by bodyweight was greater in MI-IUGR and 
less in MI-IUGR+C lambs compared to controls. Brainweight by bodyweight was 
greater in MI-IUGR and MI-IUGR+C lambs compared to controls.a,b,c,d,e Means 
with differing superscripts differ.  
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Figure 2-7. Plasma insulin concentrations (ng/mL) at basal and hyperglycemic states 
and glucose/insulin ratio (mg/dL:ng/mL) during square-wave hyperglycemic clamp 
in control (n=8), MI-IUGR (n=6), and MI-IUGR+C (n=6) lambs. 
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Figure 2-8. Hindlimb-specific insulin stimulated glucose oxidation (A) and glucose 
uptake (B) rates, respectively in control (n=8), MI-IUGR (n=6), and MI-IUGR+C 
(n=6) lambs. 
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Figure 2-9. Ex vivo primary skeletal muscle glucose uptake (A) and oxidation (B) 
under basal, insulin-stimulated, and TNF⍺-spiked conditions in control (n=8), MI-
IUGR (n=6), and MI-IUGR+C (n=6) lambs. a,b,c Means with differing superscripts 
report main effect of group and differ.   
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Chapter 3: Changes in myoblast responsiveness to TNFα and 
IL-6 and increased expression of autophagy-associated 
pathway components contribute to intrinsic myoblast 
dysfunction in intrauterine growth-restricted fetal sheep. 
 
Abstract 
 Intrauterine growth restriction (IUGR) is linked to lifelong deficits in muscle 
mass due to intrinsic functional deficits in myoblasts, but the underlying mechanisms for 
this dysfunction are unknown. Inflammatory cytokines play a central role in regulating 
myoblast function and muscle growth, and thus the objective of this study was to assess 
the functional responsiveness of primary IUGR fetal myoblasts to TNFα and IL-6 in 
culture and to examine potential changes in growth-regulating pathway components 
during incubations with an IKK inhibitor (TPCA-1). Maternal hyperthermia was used to 
induce placental insufficiency and produce IUGR fetuses (n = 7; thermoneutral controls, 
n = 7) in pregnant sheep. Primary myoblasts were isolated from fetal skeletal muscle at 
0.9 of gestation and their functional capacity was assessed after 3d in complete growth 
media (20% FBS) that was un-spiked (basal) or spiked with TNFα (20ng/ml) in the 
presence and absence of TPCA-1 (5µM), or spiked with IL-6 (1ng/ml) alone. A fetal 
experimental group by culture media interaction was observed (P < 0.05) for myoblast 
proliferation. Proliferation rates of IUGR myoblasts were less (P < 0.05) than control 
myoblasts after 3d in basal or IL-6 spiked growth media but did not differ between 
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groups in TNFα-spiked growth media. Growth media spiked with TNFα decreased (P < 
0.05) proliferation rates in control myoblasts compared to their rates in basal media. 
However, proliferation of IUGR myoblasts did not differ among basal, IL-6-spiked and 
TNF-spiked media all of which were lower (P < 0.05) than control myoblasts in basal 
media. Administration of TPCA-1 decreased (P < 0.05) proliferation rates in both control 
and IUGR myoblasts compared to their respective rates without it. The magnitude of this 
reduction was greater (P < 0.05) in IUGR myoblasts than in controls in both basal and 
TNF⍺-spiked media. Fewer (P < 0.05) IUGR myoblasts were myogenin+ compared to 
controls after 3-day incubation in basal, IL-6-spiked, or TNF-spiked differentiation media 
(2% FBS). In both experiment groups, TNF-spiked differentiation media reduced (P < 
0.05) myogenin+ myoblasts compared to basal and IL-6 spiked media. After 3d in basal 
differentiation media, fewer (P < 0.05) IUGR myoblasts were desmin+ than controls. 
However, desmin+ myoblasts did not differ between groups when cultured in IL-6-spiked 
or TNF-spiked media. Differentiation media spiked with either cytokine reduced (P < 
0.05) percentages of desmin+ myoblasts compared to basal media in controls but not in 
IUGR myoblasts, as IUGR myoblasts exhibited low percentages of desmin+ cells in basal 
media. mRNA expression for Toll-like receptor 4 (TLR4) was increased (P < 0.05) in 
myoblasts from both fetal groups when differentiation media was spiked with TNFα but 
to a greater (P < 0.05) extent in IUGR myoblasts than in controls. Expression for Tumor-
necrosis factor receptor 1 (TNFR1) and Unc-like kinase 2 (ULK2) was greater (P ≤ 0.05) 
in IUGR myoblasts than in controls in all media types. Myoblast Interleukin 6 receptor 
(IL6R) mRNA expression was not different between fetal groups or among media types. 
Semitendinosus muscle collected from IUGR fetuses at the same time as myoblasts 
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exhibited greater (P < 0.05) Interleukin 6 (IL-6) and TNFR1 mRNA expression, less (P < 
0.05) IκB protein content, and greater (P < 0.05) c-Fos protein content than controls. We 
conclude that multiple inflammatory pathways are enhanced in IUGR muscle/myoblasts, 
which contributes to the diminished functional capacity of IUGR fetal myoblasts by 
intrinsically altering their functional regulation. Furthermore, IUGR fetal adaptations 
increased mRNA expression for key components of mitochondrial autophagy pathways 
in myoblasts, which are important to cellular survival. Together, these mechanisms may 
help to explain reduced muscle hypertrophy in the IUGR fetus. 
  
 62 
Introduction 
 Intrauterine growth restriction (IUGR) disproportionately reduces muscle mass in 
fetuses and offspring (Padoan et al., 2004; Yates et al., 2014; Yates et al., 2018). We 
recently found that IUGR fetal myoblasts exhibit intrinsic functional deficits (Yates et al., 
2016; Yates et al., 2018), but have not previously identified the underlying mechanisms 
responsible for this dysfunction. Myoblasts are tightly regulated by inflammatory factors 
(Paulin and Li, 2004; Yates et al., 2018), and programmed changes within this system 
due to chronic intrauterine stress may represent one underlying molecular mechanisms 
for impaired IUGR myoblast function (Yates et al., 2014; Cadaret et al., 2017). Tumor 
Necrosis Factor-alpha (TNFα) and Interleukin-6 (IL-6) are potent multifunctional 
cytokines involved in systemic and localized inflammatory responses (Tüzün et al., 
2006). We recently found that skeletal muscle mRNA expression for TNFR1 (TNFα 
receptor) and IL6R (IL-6 receptor) were greater in near-term IUGR rat fetuses (Cadaret et 
al., 2017). Both of these cytokines regulate myoblast proliferation and differentiation (Al-
Shanti et al., 2008) and thus are essential factors in normal growth and development of 
muscle. Therefore, we postulate that developmental changes in inflammatory regulation 
of IUGR myoblasts contribute to their decreased functional capacity. In addition, the 
IUGR fetal environment is characterized by nutrient restriction, hypoxia, and chronic 
exposure to stress factors (Macko et al., 2016; Rozance et al., 2018). Recent studies have 
implicated the activation of mitophagy and autophagy pathways in response to nutrient 
deprivation and chronic stress as mediators of metabolic dysfunction and poor muscle 
growth (Hosokawa et al., 2009; Yan et al., 2012). The Unc-51-like kinase 2 (ULK2)-
mediated activity of these pathways after initial activation by TNFα/TNFR1 signaling has 
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been implicated in the pathology of Type II diabetes via mitochondrial dysfunction in 
skeletal muscle (Yan et al., 2012; Yang et al., 2015). The activation of the I𝜿B kinase 
(IKK) complex is a critical step in both the TNFα/TNFR1-mediated activation of NF𝜿B 
signaling pathways, and in the induction of autophagy and mitophagy in skeletal muscle 
(Karin, 1999; Mourkioti and Rosenthal, 2008c; Criollo et al., 2010). Thus, the objective 
of this study was to determine whether programmed changes in inflammatory regulation 
and in IKK mediated signaling pathways are responsible for the impaired functional 
capacity of IUGR fetal myoblasts. We further sought to determine if these changes are 
associated with changes in mRNA expression for key components of 
mitophagy/autophagy signaling pathways. 
Materials and methods 
Animals and myoblast isolation 
 The following experiments were approved by the Institutional Animal Care and 
Use Committees at the University of Nebraska-Lincoln and The University of Arizona 
which are both accredited by AAALAC International. Columbia-Rambouillet ewes 
purchased from Nebeker Ranch (Lancaster, CA, USA) and carrying singleton 
pregnancies were used to create IUGR fetuses (n = 7). Placental insufficiency was 
induced by exposing ewes to elevated ambient temperatures (40°C, 35% RH) from the 
40th to the 95th day of gestational age (dGA), as previously described (Yates et al., 2014; 
Yates et al., 2016). Control fetuses (n = 7) were from pair-fed ewes maintained at 25°C. 
Ewes were euthanized and necropsied at 134 ± 1 dGA and myoblasts were isolated from 
fetal hindlimb muscle as described (Yates et al., 2014). Briefly, fetal semitendinosus 
muscles were dissected from the hindlimb of each fetus. Muscles were washed with cold 
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PBS containing 1% antibiotic-antimycotic (AbAm; Gibco Life Technologies, Grand 
Island, NY, USA) and 0.5% gentamicin (Gibco) before being finely minced and divided 
into 50-ml tubes (~5 g tube-1). Minced muscle was then washed, re-suspended in PBS 
containing 1.25 mg/ml protease type XIV from Strept. griseus (Millipore-Sigma, St 
Louis, MO, USA), and digested at 37ºC for 1 hour to liberate myoblasts. After digestion, 
samples were serial-centrifuged (500 x g, 10, 8, and 1 minute) and the supernatant was 
collected and centrifuged (1500 x g, 5 minutes) a final time to pellet the isolated 
myoblasts. Cellular pellets were re-suspended in DMEM (Gibco) containing 10% fetal 
bovine serum (FBS, Atlas Biologicals, Ft Collins, CO, USA), 1% AbAm, and 0.5% 
gentamicin and incubated for 2 hours (37°C; 95% O2, 5% CO2) to remove fibroblasts. 
Purified myoblasts were grown in complete growth media (DMEM containing 20% FBS, 
1% AbAm, and 0.5% gentamicin) on fibronectin-coated culture plates (10 µg ml-1; 
Millipore-Sigma) for 24 hours, lifted from plates with Accutase (Gibco), re-suspended in 
complete growth media containing 10% dimethyl sulfoxide (Millipore-Sigma), slowly 
frozen, and stored in liquid nitrogen.  
Myoblast functional studies 
 Myoblasts were quickly thawed at 37°C and pre-plated in DMEM containing 10% 
FBS for 2 hours (37°C; 95% O2, 5% CO2) prior to treatment. To determine purity of 
myoblast isolates, a subsample of cells were stained for the myoblast marker pax7 as 
previously described (Cadaret et al., 2017), and isolates from all fetuses were ≥96% 
pax7+. To determine proliferative capacity, myoblasts were plated at 5,000 cells well-1 on 
fibronectin-coated 6-well culture plates, grown for 3 days in complete growth media, and 
then incubated for 24 hours in complete growth media containing either no additive 
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(basal), IL-6 (1ng/ml; Sigma) ,or TNFα (20ng/ml; Sigma) in the presence or absence of 
the I𝜿B kinase inhibitor TPCA-1 (IKKi 5µM; ApexBio Technology, Houston, TX, 
USA). Myoblasts were then pulse-labelled with EdU (10nM; Thermo Fisher), which is 
incorporated into replicated DNA for 2 hours. Myoblasts were then cooled on ice for 2 
minutes, lifted from plates with Accutase (Sigma), and fixed in suspension with 4% 
paraformaldehyde (PFA; Millipore Sigma) for 10 minutes. To determine differentiation 
capacity, a second set of myoblasts were plated at 20,000 cells well-1 as described above 
and cultured for 3 days in differentiation media (DMEM containing 2% FBS, 1% AbAm, 
and 0.5% gentamicin) that contained no additive (basal), 20ng/ml TNFα, or 1ng/ml IL-6. 
After 3 days, cells were cooled, lifted from plates, and fixed in 4% PFA as described 
above. All media were changed daily. 
Immunocytochemistry 
 Proliferation rates were calculated as the percentage of myoblasts incorporating 
EdU (i.e. undergoing DNA replication) during the 2-hour pulse period. These cells were 
identified by staining for EdU in suspension using the ClickIT® EdU Alexa Fluor® 555 
Cell Proliferation Assay Kit (Life Technologies) according to the manufacturer’s 
recommendations. Briefly, fixed cells were incubated in 200 µL of a 
permeabilization/blocking buffer comprised of PBS containing 1% bovine serum albumin 
(BSA; Millipore Sigma), 2% FBS, and 0.5% Triton X-100 (Millipore Sigma) for 10 
minutes at 4ºC. Cells were then pelleted by centrifuge (400 x g, 5 minutes) and re-
suspended in 100 µL of ClickIT® reaction cocktail prepared according to manufacturer’s 
recommendations. After incubating at room temperature for 30 minutes, cells were 
pelleted, washed twice, and re-suspended in Moxi Cyte Reagent (ORFLO Technologies, 
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Ketchum, ID) for analysis. Differentiated myoblasts were identified by staining with 
antiserum raised in the mouse against myogenin (F5B; 1:50; BD Pharmingen) or desmin 
(DE-U-10; 1:250; GeneTex). Primary antibodies were diluted in permeabilization / 
blocking buffer comprised of PBS containing 5% FBS, 0.5% Saponin (Millipore Sigma), 
and 2% BSA, which was applied for 1 hour at room temperature. Afterward, myoblasts 
were pelleted, washed, and incubated for 1 hour at room temperature with secondary 
affinity purified anti-mouse IgG PE-Conjugate antibody (1:250; Cell Signaling). Cells 
were then washed twice and re-suspended in Moxi Cyte Reagent for analysis. All 
samples were analyzed on a zEPI flow cytometer (ORFLO Technologies), with gates set 
from negative controls produced by incubating a subset of cells from each fetus in 
permeabilization / blocking buffer containing no primary antibody.  
RNA extraction and preparation 
Transcript expression was measured in differentiated myoblasts from parallel 
cultures performed for each fetus as described above and in samples of fetal 
semitendinosus muscle collected and snap frozen at necropsy. Myoblasts were lysed on 
the plate with 600 µl RLT buffer (Qiagen, Valencia, CA) and stored at -80ºC. Total RNA 
from myoblast lysates and from homogenized skeletal muscle was isolated with the 
RNeasy kit (Qiagen), including on-column DNase digestion with the RNase-Free DNase 
set (Qiagen) according to manufacturer recommendations. To calculated RNA 
concentrations and quality, isolates were analyzed on a Take3 plate with an Epoch 
Spectrophotometer System (BioTek, Winooski, VT), and all samples produced a 260/280 
ratio ≥ 2.0. Isolated RNA was reverse transcribed into cDNA using the QuantiTect 
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reverse transcription kit (Qiagen). Samples were then diluted at 1:10 in RNase-free water 
(Qiagen) and stored at -20ºC.  
Gene expression 
Primer design.  
Primers and probes for analysis of myoblast gene expression were designed using 
the Primer3 system (Untergasser et al., 2012), according to the recommended criteria for 
use with ddPCR supermix for probe (No dUTP) based assays (Bio-Rad, Hercules CA, 
USA). These were validated for target specificity using both National Center for 
Biotechnology and Information primer design tools and the BLAT function of the UCSC 
genome browser (University of California, Santa Cruz CA). Optimized sequences were 
purchased as PrimeTime® probe assays from Integrated DNA Technologies (IDT; 
Coralville, IA), re-suspended in IDTE buffer (IDT) to a stock concentration of 10X, and 
stored at -20ºC. PrimeTime® probe assays were prepared using the recommended 10X 
stock concentration protocol (IDT), yielding a final 1X concentration of 500 nM for each 
primer and 250 nM for probes per reaction. For analysis of skeletal muscle gene 
expression, oligonucleotide primers were synthesized as previously described (Tüzün et 
al., 2006; Al-Shanti et al., 2008), and primer pairs were obtained from IDT. The complete 
list of optimized primers and probes for each target gene is summarized in Table 3-1. 
Myoblast gene expression.  
Droplet digital PCR (ddPCR) analysis was performed in a duplex format by co-
amplifying the target gene of interest labelled with FAM and the housekeeping gene 
ribosomal protein L19 (RPL19) labelled with HEX. Quantification was performed using 
11 µl of a 2X concentration of QX200 ddPCR supermix for probe-based assays (Bio-
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Rad), yielding a final 1X concentration in each 22-µl reaction. Target gene primers and 
master mix were added to individual wells of a colorless 96-well PCR plate (Sigma), and 
100 ng of cDNA diluted in RNase-free water was added to individual wells to a final 
volume of 22 µl. RNase-free water was used as the negative template control. Each 
duplex was analyzed on an individual 96-well plate containing all fetuses and the 
negative control. Mixtures were vortexed and centrifuged and approximately 20,000 
droplets were generated using a QX200 Droplet Digital generator (Bio-Rad). Droplets 
were transferred to a QX200 compatible ddPCR 96-well plate (Bio-Rad) and thermal 
cycled on a C1000 Touch Thermo Cycler (Bio-Rad). Conditions were set according to 
the pre-determined annealing temperatures of designed PrimeTime® assays. The plate 
was then transferred to a QX200 Droplet Reader (Bio-Rad) and analyzed using 
QuantaSoft Analysis Pro Software (Bio-Rad). Gene expression was determined in 
duplicate for each sample. 
Skeletal muscle gene expression.  
PCR products were cloned into pCR II vectors (Invitrogen) and confirmed with 
nucleotide sequencing by The University of Arizona Genetics Core as previously 
described (Macko et al., 2016). Primer efficiency was determined, and standard curves 
were produced using plasmid DNA. Expression for each gene of interest was determined 
by qPCR using SYBR Green (Qiagen) with a 7900HT Real-Time PCR Detection System 
(Life Technologies). Samples were initially denatured (95°C for 15 minutes) and then 
amplified with 45 cycles of denaturing (96°C for 30 seconds), annealing (60–62°C for 30 
seconds), and fluorescence measurement during extension (72°C for 10 seconds). Melt 
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curves were performed after amplification to confirm product homogeneity. Gene 
expression was determined in triplicate for each sample. 
Western immunoblot   
 Intracellular protein concentrations for IκBα and c-Fos were determined in snap-
frozen fetal semitendinosus muscle. Muscle samples (~100 mg) were homogenized in 
200 μl of radioimmunoprecipitation buffer containing manufacturer-recommended 
concentrations of Protease and Phosphatase Inhibitor (Thermo Fisher). Homogenates 
were sonicated and centrifuged (14,000 x g for 5 minutes at 4ºC) to separate the 
supernatant. Total protein concentrations were determined with a Pierce BCA Protein 
Assay Kit (Thermo Fisher). Protein samples (35 μg) were boiled for 5 minutes at 95°C in 
BioRad 4x Laemmli Sample Buffer and separated by SDS-polyacrylamide. These gels 
were transferred to polyvinylidene fluoride low florescence membranes (BioRad) and 
incubated in Odyssey block solution (Li-Cor Biosciences, Lincoln, NE) for 1 hour at 
room temperature. They were then washed with 1X TBS-T (20 mM Tris-HCl, 150 mM 
NaCl, 0.1% Tween-20). Membranes were incubated overnight at 4ºC with antiserum 
raised in the rabbit against IκBα (1:200; Santa Cruz Biotechnologies, Dallas, TX) or c-
Fos (1:200; Santa Cruz) and diluted in Odyssey block solution containing 0.05% Tween-
20. An IR800 goat anti-rabbit IgG secondary antibody (1:5000; Li-Cor) diluted in 
Odyssey block solution with 0.05% Tween-20 and 0.01% SDS was applied for 1 hour at 
room temperature. Blots were scanned on a Li-Cor Odyssey Infrared Imaging System and 
analyzed with Li-Cor Image Studio Lite Software.   
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Statistical analysis 
 Ex vivo myoblast function and mRNA expression data were analyzed for effects 
due to fetal experimental group, culture media, and their interaction by ANOVA using 
the Mixed procedure of SAS (SAS Institute, Cary NC, USA) with the repeated measures 
function. The subject was fetus and the group was the fetal experimental designation. For 
myoblast function, two technical replicates per incubation condition were performed and 
averaged. Data for skeletal muscle mRNA and protein expression were analyzed by one-
way ANOVA using the Mixed procedure of SAS. Myoblast mRNA expression analyzed 
by ddPCR were calculated as the number of transcript copies of target gene per µl 
normalized to the number of transcript copies of the reference gene RPL19 per µl. 
Skeletal muscle mRNA expression data measured by qPCR were normalized to 
expression of ACTB (β actin). Expression of both normalizer genes was steady between 
groups and among media types. Values are expressed as means ± SE and fetus is the 
experimental unit for all analyses.  
  
 71 
Results 
Myoblast proliferation  
 A fetal group x media type interaction was observed (P < 0.05) for myoblast 
proliferation rates (Figure 3-1). Proliferation was less (P < 0.05) in IUGR myoblasts 
compared to controls in basal and IL-6 spiked media but did not differ between control 
and IUGR myoblasts in TNF-spiked media. In control myoblasts, proliferation was 
decreased (P < 0.05) after incubation in media spiked with TNFα compared to basal 
media, but rates did not differ between basal and TNF-spiked media. TPCA-1 decreased 
(P < 0.05) proliferation for both groups in basal and TNF-spiked media compared to 
TPCA-1 free media. IUGR myoblasts incubated in the presence of TPCA-1 had 
decreased (P < 0.05) proliferation compared to controls in both basal and TNF-spiked 
media. Proliferation rates in IUGR myoblasts were similar among basal, IL-6, and TNF-
spiked media, and between basal and TNF-spiked media in the presence of TPCA-1.   
Myoblast differentiation  
 The percentage of myogenin+ myoblasts from IUGR fetuses was less (P < 0.05) 
than the percentage from controls regardless of the type of differentiation media (Figure 
3-2). In myoblasts from both fetal groups, myogenin+ percentages were similar between 
basal and IL-6 spiked media and were decreased (P < 0.05) in TNF-spiked media. A fetal 
group x media type interaction was observed (P < 0.05) for desmin+ myoblasts (Figure 3-
3). Percentages of desmin+ myoblasts were less (P < 0.05) for IUGR fetuses compared to 
controls when incubated in basal media but did not differ between groups when incubated 
in IL-6 or TNFα-spiked media. For control myoblasts, desmin+ percentages were greatest 
 72 
(P < 0.05) in basal media and least (P < 0.05) in TNFα-spiked media. For IUGR 
myoblasts, desmin+ percentages did not differ among differentiation media types.  
Myoblast mRNA expression  
 A fetal group x media type interaction (P < 0.05) was observed for TLR4 
expression in differentiated myoblasts (Figure 3-4A). TLR4 expression was increased (P 
< 0.05) in myoblast populations from both fetal treatment groups when incubated in 
TNF-spiked media compared to basal media, but the increase in IUGR myoblasts was of 
a greater (P < 0.05) magnitude than in controls. Myoblast mRNA expression for TLR4 
was not different between fetal groups when incubated in basal or IL-6 spiked 
differentiation media. Expression of TNFR1 was greater (P < 0.05) in differentiated 
myoblasts from IUGR fetuses compared to controls regardless of differentiation media 
type (Figure 3-4B). Similarly, the expression of ULK2 was greater (P < 0.05) in 
myoblasts from IUGR fetuses compared to controls regardless of media type (Figure 3-
4C). Myoblast mRNA expression for IL6R and USP25 did not differ between fetal 
groups or among differentiation media (Figures 3-4D and E, respectively).  
Skeletal muscle gene and protein expression  
 Expression for TNFA (TNFα) did not differ between control and IUGR fetal 
semitendinosus muscles (Figure 3-5A). However, gene expression for IL6 and TNFR1 
was greater (P < 0.05) in IUGR fetal semitendinosus than in controls (Figures 3-5B and 
C, respectively). Semitendinosus content of IκBα protein was less (P = 0.05) in IUGR 
fetuses compared to controls (Figure 3-6A). Conversely, semitendinosus content of c-Fos 
protein was greater (P < 0.05) in IUGR fetuses compared to controls (Figure 3-6B). 
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Discussion 
In this study, we show evidence that IUGR fetal myoblasts may have inherently 
greater responsiveness to the multifunctional effects of TNFα and IL-6, leading to 
disruptions in their functional capacity to proliferate and differentiate. These findings 
help to explain the impaired skeletal muscle growth previously observed in IUGR fetuses 
(Yates et al., 2014; Cadaret et al., 2018). Incubation with TNF⍺ decreased ex vivo 
proliferation, and both TNF⍺ and IL-6 decreased differentiation rates in control 
myoblasts. However, IUGR myoblasts proliferated and differentiated at lower rates with 
or without the addition of exogenous cytokines. Administration of an IKK inhibitor 
resulted in decreased proliferation in all fetal myoblasts under both basal and TNF-spiked 
conditions. This indicates inflammatory stimulation was enhanced even under basal 
conditions. This effect was greater in IUGR myoblasts in both media. Moreover, 
transcript expression patterns in IUGR myoblasts and semitendinosus muscle were 
consistent with a change in their responsiveness to inflammatory factors, making them 
more sensitive to the small amounts of endogenous cytokines either contained in the 
serum-spiked media or produced by the cells themselves (Podbregar et al., 2013). 
Enhanced sensitivity and immunomodulatory changes in these IUGR myoblasts may 
provide the molecular mechanism to explain their previously observed intrinsic 
functional deficits (Brown, 2014; Yates et al., 2014; Soto et al., 2017). These changes 
could make IUGR myoblasts respond differently to IL-6 and TNFα-induced inhibition 
even when the circulating and local expression levels are at resting concentrations. 
Alternatively, these deficits might be due intrinsic adaptations within inflammatory 
signaling pathways that render them less responsive to cytokines. A similar phenotype 
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could manifest due to increased expression of survival elements downstream of NF𝜿B, 
which has been previously shown to increase TNFR1 expression while simultaneously 
counteracting its apoptotic signaling pathways (Puimège et al., 2014; Ting and Bertrand, 
2016). If this is indeed the case, then the apparent enhanced sensitivity could be a 
compensatory mechanism to maintain signaling function in the presence of increased 
NF𝜿B signaling activation (Figure 3-7). This would reflect a survival-oriented signaling 
response to cytokine stimulation, rather than an enhanced sensitivity to these 
multifunctional signaling molecules. Indeed, when treated with an IKK inhibitor, both 
control and IUGR myoblasts demonstrated decreased proliferation. IUGR myoblast 
proliferation was less than controls in TNF-spiked media when IKKi was present 
indicating that select TNF⍺ signaling pathways are altered in IUGR myoblasts to 
possibly promote cell survival. Interestingly, our results also indicate that these two 
cytokines had differing effects on normal myoblast differentiation. TNFα reduced 
markers of early (myogenin+) and late (desmin+) differentiation in control myoblasts but 
IL-6 reduced desmin+ myoblasts only, indicating that TNF⍺ may be a more potent 
inhibitor of fetal myoblast differentiation than IL-6. Together, these findings show that 
IUGR fetal conditions induce programming responses in skeletal muscle that may 
modulate the inflammatory regulation of myoblasts, which diminishes their capacity to 
function and facilitate hypertrophic muscle growth. These altered pathways may 
represent key molecular mechanisms that help to explain the link between stress-induced 
fetal adaptations and lifelong reductions in skeletal muscle mass in IUGR-born 
individuals. Diminished proliferation rates in IUGR myoblasts incubated IKKi in TNF-
spiked media indicate that these cells rely in part on NF𝜿B-associated survival pathways 
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to mitigate the effects of increased inflammatory signaling. However, further analysis of 
alternative pathways with similar effects on proliferation and differentiation are needed to 
identify how inflammatory modulation is altered in IUGR-born individuals.  
 Analyses of specific gene transcripts and proteins involved in canonical 
inflammatory pathways show for the first time that intrinsic deficits in IUGR myoblasts 
coincide with molecular changes that may enhance inflammatory signaling pathway 
coupling. Fetal IUGR myoblasts and skeletal muscle exhibited increased mRNA 
expression for the well-characterized inflammatory receptor TNFR1, which we postulate 
augmented TNFα-associated action relative to controls despite similar TNFα 
concentrations in culture media and similar skeletal muscle mRNA expression for TNFα. 
The apparent enhancement of TNFα sensitivity was further supported by the greater 
capacity for TNFα-spiked culture media to induce TLR4 expression in primary IUGR 
myoblasts compared to controls. Greater TNFα/TNFR1 activity combined with the 
potential for greater TLR4 activity represents a possible mechanism for increased 
autophagy and mitophagy within IUGR myoblasts via activation of the IKK complex 
(Fitzgerald et al., 2004; Criollo et al., 2010). As illustrated in Figure 3-8, IKK increases 
activity of NFκB, a keystone of canonical inflammatory signaling, by facilitating the 
ubiquitination and degradation of its arrest protein, IκBα (Karin, 1999). It also plays a 
non-canonical role in stress-associated stimulation of autophagy/mitophagy pathways by 
increasing ULK2, a key factor in nutrient deprivation-induced autophagy (Lee and 
Tournier, 2011). Indeed, we observed that IUGR skeletal muscle contained reduced 
amounts of IκBα and IUGR myoblasts exhibited greater gene expression for ULK2. We 
further found that IUGR skeletal muscle had increased amounts of c-Fos, which is 
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induced by TNFα (Haliday et al., 1991; Tu et al., 2013) and has been shown to impair 
myoblast differentiation by interfering with myoD and myogenin (Li et al., 1992; 
Trouche et al., 1993; Waskiewicz and Cooper, 1995; Rivard et al., 2000; Wozniak et al., 
2005). These observations indicate that IUGR fetal muscle expressed greater 
inflammatory signaling activity despite the normally immunosuppressive in utero 
conditions during pregnancy (McCracken et al., 2004), which would be consistent with 
human studies showing greater inflammatory cytokine concentrations in cord blood 
(Laskowska et al., 2006). The entirety of the changes that occur within these 
inflammatory pathways has not been fully assessed, but the greater apparent activity of 
these pathways was not associated with changes in expression of USP25, which mediate 
both inflammatory responses and skeletal muscle differentiation (Bosch-Comas et al., 
2006; Zhong et al., 2013). Moreover, gene expression for the IL-6 receptor remained 
unchanged between our fetal groups and among incubation conditions, although 
expression for the ligand itself was increased in IUGR skeletal muscle. Thus, IL-6 
signaling activity may have been increased by greater ligand gene expression, whereas 
TNFα signaling activity was enhanced at the level of its receptor and downstream 
signaling components. Nevertheless, it appears that enhanced TNFα/TNFR1 affected 
NFκB-associated and NFκB-independent pathways downstream of IKK, as demonstrated 
by reduced muscle IκB content and increased myoblast ULK2 gene expression, 
respectively. These findings implicate adaptive changes in pathways downstream of IKK 
associated with nutrient sensing, stress responses, and cellular survival in the 
development of the IUGR phenotype (Limesand et al., 2009; Thorn et al., 2009) and a 
molecular mechanism for reduced muscle mass and impaired skeletal muscle growth. 
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  Intrinsically-reduced proliferation and differentiation in IUGR myoblasts restricts 
muscle growth, which is beneficial to fetal survival of intrauterine nutrient deprivation 
and hypoxia but also predisposes offspring to metabolic health disorders (Yates et al., 
2012). Because cytokines play an essential regulatory role in muscle growth and 
development (Djavaheri-Mergny et al., 2006; Limesand et al., 2007; Al-Shanti et al., 
2008), the adaptive mechanisms observed in this study may help to explain smaller 
muscle fibers and reduced muscle mass in IUGR fetuses (Yates et al., 2014; Yates et al., 
2016), which in turn helps explain their impaired glucose homeostasis (Godfrey and 
Barker, 2000; Cadaret et al., 2018). Although not measured in the present study, this is 
could perhaps be due to the non-canonical activation of JNK/MAPK by TNFR1-mediated 
activation of IKK pathways involved in the mitophagy of mitochondria in response to 
cellular stress (Yan et al., 2012; Yang et al., 2015). TRAF2-mediated activation of 
JNK/MAPK pathways by stress would explain increases in c-Fos (Fitzgerald et al., 2004; 
Limesand et al., 2007; Brown et al., 2015) and its associated pathways that are implicit 
regulators of myoblast-facilitated skeletal muscle growth (Li et al., 1992; Trouche et al., 
1993; Rivard et al., 2000). Furthermore, coinciding stimulation of survival-oriented anti-
autophagic pathways via canonical IKK-NFκB activation (Reid and Li, 2001; Yan et al., 
2012) may help to explain how muscle fiber size and oxidative metabolic phenotypes are 
reduced without a loss in fiber numbers (Limesand et al., 2007; Yates et al., 2014; Brown 
et al., 2015; Yates et al., 2016). In TNF-spiked media, IUGR myoblasts demonstrated 
decreased proliferation rates when only when IKKi was added. This would indicate that 
some level of IKK-associated signaling within these cells differs from controls allowing 
them to proliferate at rates similar to control myoblasts in the presence of TNF⍺ in spite 
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of an enhanced inflammatory signaling response. Increased ULK2 activity would further 
contribute to IUGR-associated metabolic dysfunction, as increased autophagy and 
mitochondrial degradation has been implicated in the pathogenesis of Type II diabetes 
(Yan et al., 2012). These insights implicated the activation of mitophagy/autophagy 
pathways by an altered inflammatory signaling response in the development of the IUGR 
phenotype. This represents a promising avenue of further study to fully understand how 
this complex interaction might be occurring, and whether it is indeed due to an enhanced 
TNFR1 signaling system. Although TNFR1-associated signaling appears to be 
responsible for initiating this response in our study, activation of the IKK pathway can 
occur through a number of different signal transduction systems separate from 
inflammatory signaling. If inflammatory responsiveness is indeed altered within IUGR-
myoblasts then this increase in autophagy could represent a compensatory response to 
increased NF𝜿B-mediated activity, which previous studies have shown TNFR1 signaling 
to inhibit (Qing et al., 2007; Criollo et al., 2010). Thus, the observed increases in TNFR1 
could be due to increased NF𝜿B signaling in the absence of altered canonical constitutive 
TNFR1 signaling downstream of expression (Criollo et al., 2010; Puimège et al., 2014). 
Alternatively this activation could be due to other, yet unidentified, pathways that are 
differentially expressed within the IUGR phenotype downstream of IKK such as 
increases in beta-adrenergic signaling pathways or hypoxic responses both of which have 
also been implicated in the IUGR phenotype and activation of autophagic pathways (Yan 
et al., 2012; Farah et al., 2014)  It is worth noting that this outcome can be stimulated by 
TNFα via TRAF2-mediated activation of JNK/MAPK pathways (Yang et al., 2015) and 
by TLR4 via activation of the IKK complex (Reyna et al., 2008; Criollo et al., 2010). 
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However, more robust studies need to be conducted to establish if these pathways 
downstream of IKK are indeed differentially expressed in IUGR myoblasts, and to 
determine what proteins and genes are responsible for this phenotype. The identification 
of potential differential activation of autophagy/mitophagy-associated pathways 
represents a novel avenue of further research, as we continue to attempt to identify the 
adaptations that occur in IUGR-individuals. 
Conclusions 
 Fetal adaptations that result from IUGR may alter the responsiveness of skeletal 
muscle stem cells to inflammatory factors, especially cytokines. These programmed 
changes, which mostly likely follow chronic inflammatory exposure and nutrient 
restriction in utero, may also be linked to cellular autophagy/mitophagy pathways 
associated with long-term nutrient deprivation. In IUGR myoblasts, changes were 
observed in pathways associated with the pleiotropic cytokines TNFα and IL-6. These 
changes appeared to increase pathway components associated with the anti-apoptotic 
effects of IKK-mediated NFκB activation, pro-mitophaghic and autophagic effects via 
ULK2 upregulation, and disrupted differentiation via c-Fos upregulation, all of which 
help to explain reduced hypertrophy in IUGR skeletal muscle fibers without a reduction 
in fiber number. Our findings in cultured IUGR myoblasts indicate that they could 
possibly demonstrate altered inflammatory activity independent of their environment, 
thus providing one potential molecular mechanism to explain their intrinsic dysfunction. 
Together, our findings show that IUGR fetal skeletal muscle adaptations alter the 
response of myoblasts to regulatory cytokines by possibly enhancing both canonical and 
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non-canonical pathways involved in myoblast function, metabolism, and cellular 
survival.  
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Table 3-1. Primer and oligo sequences for ddPCR and qPCR.  
Gene Protein Primer Sequence Product Size Accession Number 
  ddPCR Primers   
RPL19 60S Ribosomal Protein L19 
GCAGACAAGGCTCGCAAG 
CTAACACAACAGCTGGGCAG 
HEX-TGGCGTAAGTTCTGAGGCAT-ZEN/IB FQ 
100  NC_019468.2 
TLR4 Toll-like Receptor 4 
CAGATGCAGAGACCAACCCG 
CACTGAACACACCCTGCATC 
6-FAM-TCCACCTGAGGAGGAGAATC-ZEN/IB FQ 
100 NM_001135930 
TNFR1 TNFα Receptor 1 
CACCCGCAAAATAGCACCAT 
AGAGAAAGAAGCAGGGCCTC 
6-FAM-CCAAGTGCCACAAAGGTAGG-ZEN/IB FQ 
100 NM_001166185 
IL6R IL-6 Receptor 
AACAGAGGCTACTTCTTCCCC 
GGCAGTGAGGAGCGACTTAT 
6-FAM-TAATGGGTAGGCCTAGCAGC-ZEN/IB FQ 
100 NC_019458.1 
ULK2 Unc51-like Kinase 2 
CACCTGTTGCCTGTTCCATC 
CTGACGGAACTGCTCAGGAA 
6-FAM-TTCCTTCTCTCAGTGGGCAC-ZEN/IB FQ 
100 NC_019468.2 
USP25 Ubiquitin-specific Peptidase 25 
ACCAAGGCATCACATGAGCA 
ATCTCGTGAACATGGATGGGT 
6-FAM-TGAAACAGTTTTGCAGTCGGT-ZEN/IB FQ 
100 NC_019458.2 
  qPCR Primers   
ACTB β Actin GCGGCATTCACGAAACTACC CCAGGGCAGTGATCTCTTTCTG 147 NM_001009784 
IL6 Interleukin 6 (IL-6) TTCACAAGCGCCTTCAGTCC TCTGCTTGGGGTGGTGTCAT 120 NM_001009392 
TNFA Tumor necrosis factor α (TNFα) 
CATCAAGAGCCCTTGCCACA 
CGGCAGGTTGATCTCAGCAC 130 NM_001024860 
TNFR1 TNFα Receptor 1 CTGGTGATTGTCTTTGGGCTTT AGCGACATGCTAAAACCACAGA 61 NM_001166185 
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Figure 3-1. Proliferation rates in primary IUGR fetal myoblasts incubated for 24 
hours in complete growth media (20% FBS) containing no additive (basal), TNFα 
(20 ng ml-1) in the presence or absence of TPCA-1 (5µM) or spiked with IL-6 (1 ng 
ml-1) alone. Cells were pulsed with 10nM EdU for 2 hours. a,b,c,d means with 
different superscripts differ (P < 0.05). N-value represents pairs of one IUGR and 
one control animal’s isolated myoblasts.  
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Figure 3-2. Percentages of myogenin+ primary IUGR fetal myoblasts after 4-day 
differentiation in media containing no additive (basal), TNFα (20 ng ml-1), or IL-6 (1 
ng ml-1). Differences (P ≤ 0.05) were observed for main effects of fetal treatment and 
differentiation media, but no interaction between these main effects was observed. 
N-value represents pairs of one IUGR and one control animal’s isolated myoblasts. 
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Figure 3-3. Percentages of desmin+ primary IUGR fetal myoblasts after 4-day 
differentiation in media containing no additive (basal), TNFα (20 ng ml-1), or IL-6 (1 
ng ml-1). a,b,c means with different superscripts differ (P < 0.05). N-value represents 
pairs of one IUGR and one control animal’s isolated myoblasts. 
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Figure 3-4. Gene expression (ddPCR) for (A) TLR4, (B) TNFR1, (C) ULK2, (D) 
IL6R, and (E) USP25 in primary IUGR fetal myoblasts after 4-day differentiation in 
media containing no additive (basal), TNFα (20 ng ml-1), or IL-6 (1 ng ml-1). a,b,c,d 
means with different superscripts differ (P < 0.05). 
 
 
 
 
 
 
 
a ab
c
ab b
d
0
2
4
6
Basal IL6 TNFa
TL
R
4
G
en
e 
Ex
pr
es
si
on
C
op
ie
s 
/ R
P
L1
9
Control
IUGR
A.
Figure 4
a
b
0
0.1
0.2
Control IUGR
TN
FR
1
G
en
e 
Ex
pr
es
si
on
C
op
ie
s 
/ R
P
L1
9
a
b
0.2
0.4
0.6
Control IUGR
U
LK
2
G
en
e 
Ex
pr
es
si
on
 
C
op
ie
s 
/ R
P
L1
9
B.
C.
0.3
0.4
0.5
0.6
0.7
Basal IL6 TNFa
IL
6R
G
en
e 
Ex
pr
es
si
on
C
op
ie
s 
/ R
P
L1
9
0
0.1
0.2
0.3
Basal IL6 TNFa
U
S
P
25
G
en
e 
Ex
pr
es
si
on
C
op
ie
s 
/ R
P
L1
9
D.
E.
l               IL-6              TNFα
l               IL-6             TNFα
               IL-6              TNFα
 86 
 
Figure 3-5. Gene expression (qPCR) for (A) TNFA (TNFα), (B) IL6 (IL-6), and (C) 
TNFR1 in semitendinosus skeletal muscle from IUGR fetal sheep. * fetal treatment 
means differ (P < 0.05). 
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Figure 3-6. Protein content (western immunoblot) for (A) IκBα and (B) c-Fos in 
semitendinosus skeletal muscle from IUGR fetal sheep. * fetal treatment means 
differ (P < 0.05). 
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Figure 3-7. Diagram of two hypothesized inflammatory programming responses that 
lead to enhanced inflammatory signaling. A) Increased expression of TNFR1 leads 
to increases in NF-𝜿B signaling via IKK activation. B) Increased intrinsic NF-𝜿B 
signaling has a positive feedback effect on TNFR1 increasing expression and leading 
to enhanced inflammatory responsivity.  
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Figure 3-8. Integrated schematic of the hypothesized adaptive changes in IUGR fetal 
skeletal muscle and myoblast signaling pathways that enhance the responsiveness to 
cytokines, impair myoblast functional capacity, and increased autophagy and 
mitophagy. 
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Chapter 4: Blood gene expression of stress-responsive genes as 
novel biomarkers for assessing stress and wellbeing in rodents 
& exotic species. 
 
Abstract 
 Sustained exposure to stress mediators like cytokines and catecholamines 
ultimately leads to alterations in the cellular expression of their targets. Stressors like 
maternofetal inflammation have been linked to the development of intrauterine growth 
restriction (IUGR), which is associated with fetal growth and metabolic adaptations that 
persist after birth. Our lab previously found that IUGR rat fetuses have increased plasma 
TNF⍺ and evidence of changes in inflammatory stress responsivity. The objective in Exp. 
1 was to assess inflammation-associated gene transcript changes in fetal and maternal 
blood pellets from Sprague-Dawley rats injected daily with saline, bacterial 
lipopolysaccharide (LPS) endotoxin, or LPS +  the non-steroidal anti-inflammatory drug 
(NSAID) meloxicam from the 9th day of gestation age (dGA) to the 11th (term = 21 
dGA). Maternal samples collected at 0, 6, and 54 hr after onset of LPS injection and fetal 
samples collected at necropsy on dGA 20, were assessed for TNF⍺, TNFR1, IL6R, Fn14, 
and INFγR1 differential expression using ddPCR. Fetal TNFR1 tended to be greater (P < 
0.10) after maternofetal inflammation (MI), but not when meloxicam was given 
concurrently. Fetal IL6R was reduced (P < 0.05) by MI and was not rescued by 
meloxicam. Maternal TNFR1 was increased (P < 0.05) by LPS at 6 hours and was not 
ameliorated by meloxicam administration. No other gene transcripts differed among 
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groups. Together, our findings demonstrate that maternofetal inflammation during mid-
gestation leads to transient maternal changes and fetal adaptations in cytokine signaling 
pathways, which are reflected in the transcriptome of circulating leukocytes. We further 
show that changes were generally not alleviated by concurrent administration of 
meloxicam. Given our findings in Exp. 1, the objective of Exp. 2 was to determine if 
differential expression of stress-responsive genes in blood samples from zoo animals 
analyzed via ddPCR could be potential stress biomarkers. Total RNA was extracted from 
whole blood of cheetahs, elephants, and giraffes. The ability to measure mRNA for 
TNF⍺, TNFR1, IL6R, IL6, IL10, ADRβ2, NR3C1 was assessed using ddPCR analysis. 
RPP30, RPL19, and YWHAZ were assessed as potential normalizers. For elephant and 
cheetah target transcript analyses, probes were designed using the assemblies published 
on the National Center for Biotechnology Information (NCBI) database. Giraffes do not 
have a published assembly available, so an cross-species technique was used to design 
primers specific to segments of the target transcripts that were predicted to be highly 
conserved among giraffe, cow, and sheep. In cheetahs (n=2), primers and probers were 
successfully validated for ADRβ2, IL10, IL6R, NR3C1, TNFR1, TNF⍺, and all three of 
our potential normalizers. However, only RPL19 had a relatively low calculated CV (7%) 
and was thus presumed to be the most suitable for this species as a normalizer. In giraffes 
(n=1), we successfully designed cross-species primers for TNF⍺ and ADRβ2, but not for 
any of our other intended targets. In elephants (n=3), primers and probes were validated 
for the quantification of ADRβ2, IL10, NR3C1, TNFR1, TNF⍺, with RPP30 appearing to 
be the most suitable normalizer (CV = 10%). The mRNA expression patterns appeared to 
parallel behavioral reports of one elephant displaying consistent high-anxiety. Together, 
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these findings indicate that differential expression of stress-responsive genes in blood is a 
promising avenue for better biomarkers capable of tracking stress and assessing 
wellbeing in zoo animals, which will be important in optimizing health status & 
reproductive capacity in these animals. This study also demonstrates that it is possible to 
design on-target primers for specific transcripts in unassembled species, such as giraffes, 
with whole genome sequences of related species.     
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Introduction 
 Multiple models of maternofetal stress including inflammation have been shown 
to induce intrauterine growth restriction (IUGR), which is linked to lifelong dysfunction 
in humans and animals (Cadaret et al., 2018; Yates et al., 2018). Inflammation induced 
by bacterial lipopolysaccharide (LPS) endotoxin have previously been linked to changes 
in immune cells and specifically with a shift toward a pro-inflammatory phenotype in 
circulating white blood cells (WBC) (Medzhitov, 2008; Martinez et al., 2014; Yuan et al., 
2016). This pro-inflammatory phenotype favors increases in TNF⍺ and IL-6, as well as 
their respective receptors TNFR1 and IL6R (Duque and Descoteaux, 2014; Martinez et 
al., 2014) in concert with a marked decrease in the expression of anti-inflammatory 
cytokines such as IL-10 (Opal and DePalo, 2000; Duque and Descoteaux, 2014). Stress-
responsive signaling pathways activated by glucocorticoids and catecholamines have 
been implicated in exacerbating this pro-inflammatory phenotype under chronic 
conditions, which further increases inflammation and contributes to the development of 
chronic diseases (Medzhitov, 2008; Liu et al., 2017). Therefore, the objective of Exp. 1 
was to determine the effects of sustained maternofetal inflammation at mid-gestation on 
maternal and fetal mRNA profiles in whole blood pellets  
 Modern zoos are expected to maintain high standards for animal wellbeing in a 
diverse population of wildlife. Zoo animals experiencing novel stressors may be at 
greater risk for inflammatory diseases, and opportunistic infections in environments that 
differ from their natural habitat. The most common indicators used to measure the 
physiological stress of zoo animals is glucocorticoid concentrations in feces, and to lesser 
extent blood, urine, or saliva. However, this assay is limited by the individual variation 
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between group-housed animals (Cockram, 2002; Wolfensohn et al., 2018), the natural 
circadian variations in glucocorticoids, that glucocorticoid release is also associated with 
non-stress stimuli, and that glucocorticoids are not always elevated by stress (Cockram, 
2002). Other measurements, such as the leukocyte or neutrophil activation test have been 
previously shown to be possible markers of stress levels (Honess et al., 2005). However, 
these tests only loosely estimate overall stress through leukocyte responsivity. Finally, 
the majority of published studies on animal wellbeing focus on markers that only apply to 
mammalian species, which represent one part most zoos taxonomic population 
(Wolfensohn et al., 2018). The objective of Exp. 2 was to determine if we could measure 
stress-responsive gene transcripts as potential biomarkers in whole blood from elephants, 
giraffes, and cheetahs using ddPCR. We further sought to design cross-species primers 
for a species with only a whole genome sequence available (giraffes), which would allow 
for the possibility of future research to be applied to a broader range of species. 
Materials and Methods 
Exp. 1 
Animals and experimental design.  
All procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Nebraska-Lincoln. Studies were performed at the 
University of Nebraska-Lincoln Animal Science Complex, which is an AAALAC 
International accredited institution. Timed-pregnant Sprague-Dawley rats (Envigo, 
Indianapolis, IN) were purchased and delivered on day 6 of gestational age (dGA). On 
dGA 8, rats were moved to individual housing, fed ad libitum commercial rat chow, and 
weighed daily. From dGA 9 to 11, rats were injected (IP) daily with 250µl saline 
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(control, n=7), 100µg/kg BW of lipopolysaccharide (LPS) from E. coli O55:B5 (Sigma-
Aldrich, ST. Louis, MO, USA) in 250µl saline to create maternofetal inflammation-
induced IUGR (MI-IUGR, n=8), or LPS concurrent with 7.5mg/kg BW of meloxicam 
(LMX, n=10). Blood samples were collected from dams via saphenous vein puncture at 
0, 6, and 54hr after initial injection. On dGA 20, rats were euthanized by decapitation 
under heavy isoflurane anesthesia after maternal blood samples were collected via heart 
puncture. Pooled fetal blood samples were collected for each litter via exsanguination. 
All blood samples were centrifuged (14,000 x g, 2 minutes, 4ºC) and blood pellets were 
re-suspended in TRI Reagent® (Sigma-Aldrich) at a 3:1 ratio to original blood volume, 
vortexed, and stored at -80ºC. 
RNA extraction and preparation.  
Gene transcripts were measured in maternal blood samples taken at 0, 6, and 54hr 
after the first injection. Fetal blood gene transcript expression was measured from 
samples taken at dGA 20 as described above. To extract RNA, samples suspended in TRI 
Reagent® were thawed to room temperature and homogenized. Chloroform (160µl) was 
added to each sample and vortexed for 10-15 seconds before incubating at room 
temperature for 5 minutes. All samples were then centrifuged (12,000 x g, 15 minutes, 
4ºC), and the aqueous layer transferred to a QiAmp® shredder column (Qiagen, 
Germantown, MD, USA). Extraction was then performed using the QiAmp® RNA Blood 
Mini Kit (Qiagen), including on-column DNase digestion with the RNase-Free DNase set 
(Qiagen) according to manufacturer recommendations. Isolated RNA concentration and 
quality was analyzed on a Take3 plate with an Epoch Spectrophotometer System 
(BioTek, Winooski, VT, USA) to ensure that all samples produced a 260/280 ratio ≥ 2.0. 
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RNA isolates were reverse transcribed into cDNA using the QuantiTect reverse 
transcription kit (Qiagen). Samples were diluted at 1:10 in RNase-free water (Qiagen) 
and stored at -20ºC.  
Primer design.  
Primers for the analysis of IL6R, TNFR1, and FN14 expression were purchased as 
PrimePCR ddPCR primers (Bio-Rad, Hercules, CA, USA) specific to the EvaGreen 
supermix based assay. Primers for the analysis of TNFA, YWHAZ, and INFGR1 were 
designed using the Primer3 system (Untergasser et al., 2012), according to the 
recommended criteria for use with ddPCR Evagreen supermix based assays (Bio-Rad, 
Hercules CA, USA). These were validated for target specificity using both National 
Center for Biotechnology and Information primer design tools and the BLAT function of 
the UCSC genome browser (University of California, Santa Cruz, CA, USA). Optimized 
sequences were purchased from Integrated DNA Technologies (IDT; Coralville, IA, 
USA), re-suspended in RNase free water to a concentration of 100µm. Forward and 
reverse primer solutions were mixed to create a 10µM working solution, which was 
stored at 20ºC. gBlocks® Gene Fragments were also purchased from IDT for YWHAZ, 
TNFR1, FN14, and IL6R.  
mRNA quantification.  
Droplet digital PCR (ddPCR) analysis was performed in duplicate using the 
QX200 system (BioRad). EvaGreen Supermix (11µl) at a 2X concentration was added to 
individual wells of a colorless 96-well PCR plate (Sigma). A 10µM working solution of 
IDT designed primers (0.22µl), or PrimePCR primers (1µl) for transcripts of interest was 
added to individual wells before 2µl of 1:10 cDNA sample was added. RNase free water 
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was then added to the master mix for a total volume of 22µl per well. RNase-free water 
was used as the negative template control, and gBlocks® Gene Fragments (IDT) for 
YWHAZ, TNFR1, Fn14, and IL6R were used as positive controls to determine the 
expression levels of those target genes. Each gene was analyzed on an individual 96-well 
plate containing all fetal and maternal samples, with a negative and positive control. 
Mixtures were vortexed and centrifuged (3,000 x g, 3 minutes, 20ºC) before 
approximately 20,000 droplets were generated using a QX200 Droplet Digital Generator 
(Bio-Rad). Droplets were transferred to a QX200 compatible ddPCR 96-well plate (Bio-
Rad) and thermal cycled on a C1000 Touch Thermo Cycler (Bio-Rad). Conditions were 
set according to pre-determined annealing temperatures of designed and PrimePCR 
primers. Expression was quantified using a QX200 Droplet Reader (Bio-Rad), and results 
analyzed using QuantaSoft Analysis Pro Software (Bio-Rad). The complete list of 
optimized primers for each target gene is summarized in Table 4-1. 
Statistical Analysis.  
All data were analyzed by ANOVA using the mixed procedure of SAS (SAS 
Institute, Cary, NC, USA) to determine experimental group effects. Repeated measures 
were used for serial maternal samples. Gene transcript data are expressed as transcript 
copies per µl, normalized to copies per µl of YWHAZ. Rat (dam) was considered the 
experimental unit and experimental group was the group for all variables. Fetal values 
reflect the pooled fetal samples analyzed in each dam’s litter. All data are expressed as 
mean ± standard error.  
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Exp. 2 
Animals and experimental design.  
All sample collections were approved by the Institutional Animal Care and Use 
Committees at the University of Nebraska-Lincoln and Omaha’s Henry Doorly Zoo and 
Aquarium. Giraffe (n=1) and elephant (n=3) samples were collected into TempusTM 
blood RNA tubes (Applied Biosystems, Foster City, CA, USA), and stored at 4ºC for a 
max of 72hr. Cheetah samples (n=2) were collected using the TRI Reagent (Sigma-
Aldrich) protocol described in Exp. 1.  
RNA extraction and preparation.  
Elephant and giraffe samples collected into Tempus™ blood RNA tubes were 
extracted using manufacturer recommendations. Cheetah samples collected in TRI 
Reagent® were extracted using the protocol described for Exp. 1. Quality of RNA was 
determined and extracts were reverse transcribed as in Exp. 1. cDNA was stored at -20ºC 
as a 1:10 dilution for elephant and cheetah samples, and undiluted for giraffe samples.  
Probe design.  
Probes for analysis of cheetah and elephant mRNA expression were designed 
using the Primer3 system (Untergasser et al., 2012), according to the recommended 
parameters for use with ddPCR supermix for probe (No dUTP) based assays (Bio-Rad). 
Sequences were validated using the protocol in Exp. 1 are summarized in Tables 4-2 and 
4-3. Optimized sequences were purchased as PrimeTime® probe assays (IDT), re-
suspended in IDTE buffer to a stock concentration of 10X, and stored at -20ºC. Before 
use, probe assays were prepared using the recommended 10X stock concentration 
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protocol to yield a final 1X concentration of 500nM for primers and 250nM for probes 
per reaction.  
Cross-species primer design.  
Primers for the analysis of giraffe mRNA expression were designed using a cross-
species protocol and are summarized Table 4-4. Sheep (Ovis ares) and cow (Bos taurus) 
assemblies were obtained from the Ensembl database for each target transcript. The 
coding regions were then paired against the whole genome sequence (NCBI database) for 
the giraffe (Giraffa camelopardalis tippelskirchi) using the BLAST function (NCBI) to 
determine identity percentage. Sequence segments with at least 99% identity for target 
coding regions of both sheep and cow were then aligned using MultAlin. Primers were 
designed using Primer3 (Untergasser et al., 2012) including only sequence segments that 
had 99% identity across all three species. Primers also included at least one identified 
exon that was conserved between cow and sheep sequences. Identified sequences for IL6, 
ADRB2, TNFA, and RPL19 were obtained and validated using the same protocol as 
described in Exp. 1. Optimized sequences were purchased (IDT) and working solutions 
were stored at -20ºC.  
ddPCR Analysis.  
The giraffe sample, was analyzed with the EvaGreen supermix for ddPCR 
protocol as described in Exp. 1. Cheetah and elephant ddPCR analysis was also 
performed as described in Exp. 1, with some modifications for probes. Quantification 
was performed in duplex format by co-amplifying the target transcript of interest labelled 
with FAM and the normalizer genes (RPP30, RPL19, and YWHAZ) labelled with HEX. 
Each target transcript was quantified in duplex with each normalizer gene to accurately 
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determine fold change and overall expression during analysis. A 2X concentration of 
QX200 ddPCR supermix (No dUTP) for probe-based assays (Bio-Rad) at a final 
concentration of 1X in each 22µl was used in place of the EvaGreen supermix. 
Conditions for thermal cycling were also modified to fit the pre-determined annealing 
temperatures of designed PrimeTime® assays. Data are analyzed using QuantaSoft 
Analysis Pro Software (Bio-Rad) with expression determined for each target 
gene/normalizer gene combination.  
Statistical analysis.  
Expression for all three species from ddPCR analysis was calculated as the 
number of transcript copies of target transcript per µl normalized to the number of 
transcript copies of each available reference transcript per µl. The coefficient of variation 
(CV) was determined for all references available in each group to determine their 
suitability as normalizers. The reference used was RPL19 for cheetahs, RPP30 for 
elephants, and RPL19 was targeted in giraffes.  
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Results 
 
Exp. 1  
Fetal TNFR1 tended to be increased (P < 0.10) but not when meloxicam was 
concurrently administered (Figure 4-1A). Fetal IL6R was reduced (P < 0.05) by MI and 
was not improved by concurrent meloxicam (Figure 4-1B). Maternal TNFR1 was 
increased (P < 0.05) by LPS at 6hr after initial injection and was not affected by 
meloxicam administration (Figure 4-2). No other genes differed among groups. 
Exp. 2 
 In cheetah samples, the expression of ADRβ2 (β2 Adrenoceptor), IL10 
(Interleukin 10), IL6R (Interleukin 6 Receptor), NR3C1 (Glucocorticoid Receptor), 
TNFR1 (TNF⍺ Receptor 1), and TNF⍺ (Tumor Necrosis Factor Alpha) was successfully 
quantified (Figure 4-3). Among the three normalizers, RPL19 (Ribosomal Protein L19) 
was found to have the lowest CV (7%) among the samples. In elephant samples, the 
expression of ADRB2, IL10, NR3C1, TNFR1, and TNFA were successfully quantified 
(Figure 4-4). RPP30 (Ribonuclease P/MRP Subunit P30) was the reference transcript 
with the lowest CV (10%). Cross-species primers were able to quantify ADRB2 and 
TNFA in our giraffe sample, but no other transcript was successfully quantified by our 
primers.  
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Discussion 
 In Exp. 1, we found that injection of LPS endotoxin caused temporal increases in 
the expression of TNFA and its receptor TNFR1 in circulating leukocytes of pregnant rats. 
We also demonstrated that MI at mid-gestation leads to lasting inflammatory adaptations 
in the transcript expression of the cytokine receptors IL6R and TNFR1, which were 
observed at term in fetal blood. These results indicate that inflammation and stress lead to 
changes in the transcriptome of circulating leukocytes, which can be used as biomarkers 
for stress assessment. They further demonstrate that activation of these pathways during 
mid-gestation can have lasting effects on the expression patterns of fetal leukocytes.  
 In Exp. 2 we determined if these biomarkers could be quantified in zoo species as 
well. We were able to successfully design and implement ddPCR probes for a number of 
immunological and stress-responsive genes in cheetahs and elephants, which 
demonstrates the applicability of assays targeting these biomarkers to a broad range of 
mammals. We were also able to successfully utilize a cross-species primer design 
approach to target and analyze some but not all transcripts in giraffes. This represents, to 
our knowledge, the first successful attempt at designing cross-species primers for these 
targets in this unassembled species.  
 We chose the biomarkers in this study based off of our previous experiences, and 
on the complex interactions between the stress, reproductive, and immune systems. We 
chose to target the receptors for glucocorticoids (NR3C1) and catecholamines (ADRβ2), 
as these pathways play a role in immunomodulation, the stress response, and even 
reproductive success in mammals (Padgett and Glaser, 2003; Slavich and Irwin, 2014; 
Liu et al., 2017; Levine and Muneyyirci-Delale, 2018). The results of Exp. 1 demonstrate 
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that the blood expression patterns of the cytokines TNF⍺ and IL6, as well as their 
receptors, are modulated in response to inflammation. Previous studies in mammals also 
demonstrate these cytokines pleiotropic effects on everything from mental health (Slavich 
and Irwin, 2014; Vogelzangs et al., 2016) to complex interactions with the reproductive 
and stress response systems (Morey et al., 2015; Costanza and Pedotti, 2016; Liu et al., 
2017). Finally, IL-10 was chosen because it is a major immunoregulatory and anti-
inflammatory cytokine (Opal and DePalo, 2000; Couper et al., 2008). Analysis of IL-10 
expression would allow future assays to increase the window for detection of infection 
and inflammation, as its rise would be concurrent with decreasing levels of pro-
inflammatory cytokines. It is worth noting that all of these pathways and biomarkers have 
also been identified in invertebrates and non-mammals, allowing them to be applicable to 
a more diverse range of species (Janeway et al., 2001; Müller et al., 2008; Adamo, 2012).    
 Together, the results of both experiments represent a promising avenue for future 
research into monitoring animal wellbeing, reproductive programs, and disease detection 
in zoos with diverse taxonomic populations. The biomarkers and associated pathways we 
chose to pursue in these experiments are evolutionarily conserved across most vertebrates 
and invertebrates (Müller et al., 2008; Flajnik and Kasahara, 2010; Adamo, 2012). As 
demonstrated in experiment 1, some of these stress biomarkers are differentially 
expressed in whole blood after inflammation which makes them viable targets for 
assessing disease states in animals. Other studies in mammals and invertebrates have 
demonstrated these markers are affected by stress, disease, reproductive status, and many 
other components of overall animal wellbeing (Adamo, 2012; Costanza and Pedotti, 
2016; Vogelzangs et al., 2016; Liu et al., 2017). Thus, the ability to analyze these 
 104 
expression patterns in while blood represents a new opportunity to improve our 
understanding of wellbeing in a broad range of exotic species.  
A high standard of wellbeing in diverse range exotic species is a goal for zoos 
(Wolfensohn et al., 2018). Proper care requires accurate and reliable assessment of 
physiological stress and health, which is difficult to tailor to the specific needs of species 
who may be at greater risk of mortality in these novel environments with current 
techniques that include the measurement of cortisol from the feces, urine, or saliva of 
animals and behavioral assessments (Wolfensohn et al., 2018). Both of these measures 
are limited due to individual variability, circadian variation, complex collection of 
samples of group housed populations, and their association with other non-stress stimuli 
(Cockram, 2002; Wolfensohn et al., 2018).  
We conclude that whole blood expression of stress-responsive mRNA biomarkers 
is altered due to inflammation. These and other evolutionarily-conserved biomarkers can 
be quantified in elephant, cheetah, and giraffe blood samples using species specific 
ddPCR probes and primers. We were able to design probes specific to most of our 
intended targets and were also successful in designing cross-species primers capable of 
quantifying targets in the giraffe, which is currently unassembled. It is of note that we 
were able to corroborate our findings in elephants with behavioral observations from 
keepers that indicated a high anxiety female within this family group. The results of our 
studies represent a promising future for the development of a comprehensive assay that 
can be used to identify and assess stress in diverse populations of animals housed in zoos. 
Further research is of course needed to determine the applicability of such assays to other 
non-mammalian species, and which additional biomarkers might be included.  
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Table 4-1. Rat primer sequences for ddPCR 
Gene Protein Primer Sequence Product Size 
Accession 
Number 
TNFA Tumor necrosis factor alpha 
AACTCCCAGAAAAGCAGCA 
AGAAGAGGCTGAGGCACAGA 200 NM_012675.3 
INFGR1 Interferon Gamma Receptor 1 
TGAAACATTACAGGAGTGGG 
GGACGCTATGTTCTGTATGT 48 NM_053783.1 
FN14 TWEAK Receptor CACTGATCCAGTGAGGAGCA GGCAATTAGACACCCTGGAA 88 NM_181086 
IL6R IL-6 Receptor CACGAGCCATCATGAAGAGA GCCAAGGTGCTTGGATTTTA 96 NM_017020 
TNFR1 TNFα Receptor 1 TTGTAGGATTCAGCTCCTGTC CTCTTACAGGTGGCACGAAGTT 109 NM_013091 
YWHAZ 14-3-3 protein ζ CCGAGCTGTCTAACGAGGAG GAGACGACCCTCCAAGATGA 88 NM_013011 
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Table 4-2. Cheetah primer and oligo sequences for ddPCR. 
 
Cheetah Sequences 
Gene Protein Primer Sequence Product Size Accession Number 
  ddPCR Primers   
RPL19 60S Ribosomal Protein L19 
CGGGAATGGACAGTCACAGG 
CGTCAGCAGATCCGGAAACT 
HEX-ATGGGCTGATCATCCGGAAA-ZEN/IB FQ 
100  XM_015078591 
TNF⍺ Tumor necrosis factor alpha TGGTCTGGTAGGAAACGGCA TCTTCAGGGGCCAAGGATGT 6-FAM-TTCCACACATGTGCTCCTCA-ZEN/IB FQ 100 XM_015082146 
TNFR1 TNFα Receptor 1 
GTCCCGGTACACTGTGCAAG 
AGCTGCTCCAAATGCCGAAA 
6-FAM-ATGTACCAGGTGGAGATATCTC-ZEN/IB 
FQ 
100 XM_027074099 
IL6R IL-6 Receptor 
CTCCGCAGCCAGTGAATTGT 
GCTGAGTGATGTGGTGACCG 
6-FAM-CCAACGTGACCCTGACCTG-ZEN/IB FQ 
100 XM_027048711 
IL-10 Interleukin 10 
GTGCTGTTTGATGTCCGGGT 
GACTTTAAGGTGAGGGCCCG 
6-FAM-TACTTGGAGGAGGTGATGCC-ZEN/IB FQ 
100 XM_027074588 
NR3C1 
Nuclear receptor 
subfamily 3 group C 
member 1 
GTCTGGGAAAGGAACCGTGC 
CGAACGGGACAGAAAGGTGG 
6-FAM-TCCGAGCACCACGTGATC-ZEN/IB FQ 
100 XM_027042531 
ADRβ2 Adrenoceptor beta 2 
GCTGAGATTTTGGGCGTGGA 
GGTCTTTCAGGTGGCCCAAA 
 
6-FAM-GATCGACAAATCTGAGGGCC-ZEN/IB FQ 
 
100 XM_015079810 
RPP30 Ribonuclease P/MRP subunit p30 
CTCTCAGACAGCCCGAACAG 
TGTCTAGTGCTGCGGAAAGG 
HEX-AAGAGGCCCATACGATGTGG-ZEN/IB FQ 
100 XM_015061888 
YWHAZ 
Tyrosine 3-
monooxygenase/trypt
ophan 5-
monooxygenase 
activation protein zeta 
AAGGGGCCGGCTAACATTTG 
AGGGGAATTAGTGGTGGGCA 
HEX-AGTGTCTACCCCAATTCTGGT-ZEN/IB FQ 
100 XM_027064119 
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Table 4-3. Elephant primer and oligo sequences for ddPCR. 
Elephant Sequences 
 
Gene Protein Primer Sequence Product Size Accession Number 
  ddPCR Primers   
RPP30 Ribonuclease P/MRP subunit p30 
GAGCACTGACAGAGACCGAC 
CTTCCAGCGTGCAAGAAAGC 
HEX-AAGTGTGAGGGCTGAGCAG-ZEN/IB FQ 
100  XM_003409241 
TNF⍺ Tumor necrosis factor alpha CTCAACGTCCCGGATCATGC GCTCCACCATCTCCCAGCTA 6-FAM-CCAAAGGACACCATGAGCAC-ZEN/IB FQ 100 XM_023541361 
TNFR1 TNFα Receptor 1 
GGGAGGGGAAGAGACTGCAT 
GTAGGGCCAAGAAAGGGTGC 
6-FAM-AGGGAAAGGACAAGTGGAGT-ZEN/IB FQ 
100 XM_023549042 
IL6R IL-6 Receptor 
CCAGGCTTCCATCCCACCTA 
GTCTCTCTCCTCTGCACCGT 
6-FAM-GCTCTCTTTTCCCACAGTGC-ZEN/IB FQ 
100 XM_023554017 
IL-10 Interleukin 10 
CTCTGGGGCCTACTGTTCCA 
CGGCGCTGTGTGAGTAGAAG 
6-FAM-TTTTTCCCCTGGAGGCTGTC-ZEN/IB FQ 
100 XM_023548359 
NR3C1 
Nuclear receptor 
subfamily 3 group C 
member 1 
AGACTGACCTGGTATGGGGC 
AAGCCAACACCTCTCCCAGA 
6-FAM-ACCTTAGTACAGCAAGGGTTGT-ZEN/IB 
FQ 
100 XM_003404576 
ADRβ2 Adrenoceptor beta 2 
GCAGGTCTCTTCGGCATAGC 
ACCTCCTTCTTGCCCATCCA 
 
6-FAM-AATGCACTGGTACCGGGC-ZEN/IB FQ 
 
100 XM_003404840 
RPL19 60S Ribosomal Protein L19 
AGGCTGTGATACATGTGGCG 
AGGATGAGAATTCTGCGCCG 
HEX-CTGCTCAGGAGATACCGTGA-ZEN/IB FQ 
100 XM_010594387 
YWHAZ 
Tyrosine 3-
monooxygenase/trypt
ophan 5-
monooxygenase 
activation protein zeta 
TCAACCGCTAGTGGGAGGAC 
CAGCATGCTCGAGTCCCATC 
HEX-TGTCATTCCACCTCACCTGA-ZEN/IB FQ 
100 XM_010588433 
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Table 4-4. Giraffe primer sequences for ddPCR. 
Giraffe Sequences (Assembly #: GCA_001651235.1) 
 
Gene Protein Primer Sequence Product Size Accession Number 
  ddPCR Primers   
RPL19 60S Ribosomal Protein L19 
GGGCCTTGTGTAGAAGAGCA 
ACACGTTACCCTTCACCTTCA 126 
Cow: XM_587778 
Sheep: 
XM_012186026 
TNF⍺ Tumor necrosis factor alpha TCTACTTTGGGATCATCGCC CAGGCCTCACTTCCCTACAT 201 Cow: XM_005223596 Sheep: 
XM_012100437 
IL-6 Interleukin-6 TCAGCCCTCTAGTGGTGTGA 
GCATCCATCTTTTTCCTCCA 
156 Cow: 
NM_174674 
Sheep: 
NM_001166185 
ADRβ2 Adrenoceptor beta 2 GGGGCAGCTTTGGTTGTTTT 
AAGCACACTCCAGTCAAGGG 
 
113 Cow: 
NM_174231 
Sheep: 
NM_001130154 
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Figure 4-1. Gene expression (ddPCR) for (A) TNFR1 and (B) IL6R in control (n=7), 
MI-IUGR (n=8), and MI-IUGR + Meloxicam (n=10) rat fetuses at term. a,b means 
with different superscripts differ. 
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Figure 4-2. Gene expression (ddPCR) for TNFR1 in maternal whole blood samples 
collected at 0, 6, and 54hr after treatment onset of LPS injection. a,b means with 
different superscripts differ (P < 0.05). Control (n=7), MI-IUGR (n=8), MI-IUGR + 
Meloxicam (n=10). 
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Figure 4-3. Gene expression (ddPCR) for ADRB2, IL10, TNFA, IL6R, NR3C1, and 
TNFR1 in whole blood samples collected from cheetahs (n=2). 
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Figure 4-4. Gene expression (ddPCR) for ADRB2, IL10, TNFA, NR3C1, and TNFR1 
in whole blood samples collected from elephants (n=3).  
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